Podcasts about rct

Dans cet épisode les Causeries de la Rade reviennent sur la laborieuse victoire contre Vannes et analysent ce qui ne tourne pas rond au RCT.L'occasion aussi de revenir sur l'actualité de la semaine. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

In this Wellness Tech Series episode, Nurse Doza breaks down SONA — an AI-powered earpiece that delivers gentle vagus nerve stimulation at the cymba concha, the one spot in the outer ear where a branch of the vagus nerve reaches the surface. He explains how the paired app reads heart rate variability in real time, why HRV is a window into stress and recovery, and how short guided breath and audio sessions are designed to fit a schedule with no room for a long meditation. FEATURED PARTNER SONA is an AI-powered wearable vagus nerve stimulator. It sits on the ear and delivers low-level, non-invasive electrical stimulation at the cymba concha — the auricular branch of the vagus nerve — while the companion app tracks heart rate variability so users can watch their own trend across a session. Guided breath work and audio pairings are built in, the app has no monthly subscription, and the device ships with a 30-day money-back guarantee and a 1-year warranty. It's the tool Nurse Doza reaches for when the problem isn't knowing how to relax — it's having ten minutes and a way to tell whether anything actually happened.

What if the biggest improvements to your health aren't hiding inside another supplement, expensive biohack, or complicated protocol, but in the signals you're sending your body every single day? In this special episode of the SuperLife Podcast, Darin walks through his personal daily routine from the moment he wakes up, explaining not only what he does, but why he does it. From getting outside before touching his phone to morning light, hydration, meditation, breathwork, journaling, cacao, movement, food, and eventually shutting off the breaker to his bedroom at night, Darin breaks down the practices he has built into the rhythm of his life. But this isn't a prescription to copy Darin's routine. It's an invitation to understand the biological signals behind it and build your own. Darin's central idea is simple: food is information, light is information, breath is information. Every input you give your body becomes a set of instructions your cells have to respond to. Drawing from research on circadian biology, hydration, meditation, nervous system regulation, expressive writing, cacao flavanols, resistance training, cardiovascular health, and longevity, Darin explains how simple behaviors compound over decades. The healthiest and longest-lived people he has encountered around the world didn't necessarily follow elaborate protocols. Their health was embedded into a rhythm of light, movement, real food, darkness, and sleep. This is a practical look inside the habits Darin actually uses, and a reminder that your health isn't created by one massive intervention. It's built through the seemingly insignificant decisions you repeat every day. What You'll Learn What Darin does from the moment he wakes up each morning Why he goes outside before looking at his phone How morning light helps synchronize your circadian rhythm and nighttime sleep Why hydration comes before coffee or other stimulants How meditation and conscious breathing can change your relationship with stress Why Darin considers breath one of the fastest ways to influence your nervous system How journaling can help process emotions, gratitude, grief, and mental stress Why cacao has become part of Darin's morning ritual How resistance training and aerobic movement support long-term health Why Darin believes health is ultimately about creating a biological rhythm rather than blindly following someone else's protocol Chapters 00:00:03 – Welcome to SuperLife 00:00:34 – Sponsor: Bite 00:02:49 – What Darin does before touching his phone every morning 00:03:11 – Why your biology is waiting for the signal of morning light 00:03:44 – The purpose behind Darin's daily routine 00:04:12 – Why you shouldn't simply copy someone else's protocol 00:04:37 – Food, light, and breath are information 00:05:06 – How the modern day disrupts your natural biology 00:05:51 – The danger of stacking small "fatal conveniences" for decades 00:06:20 – Why Darin built his life around biological rhythm 00:06:47 – Darin's morning hydration routine 00:07:11 – Why Darin wakes up between 4 and 5 A.M. 00:07:38 – Morning sunlight, no sunglasses, and no screens 00:07:48 – Your body's master circadian clock 00:08:40 – What research says about morning sunlight and sleep 00:09:21 – The cheapest thing you can do tonight for better sleep 00:09:44 – Why Darin drinks water before anything else 00:10:22 – Darin's daily meditation practice 00:10:54 – What research shows about mindfulness, anxiety, depression, and pain 00:11:33 – Sponsor: Fatty15 00:15:14 – Training yourself not to be hijacked by the modern world 00:15:43 – Your breath is the steering wheel of your nervous system 00:16:33 – The five-minute breathing practice that changed mood and respiratory rate 00:17:13 – How conscious breathing can shift your nervous system 00:17:42 – Darin's journaling and gratitude practice 00:18:15 – Journaling through grief after losing his mother 00:18:44 – What expressive writing research reveals about mental health 00:19:17 – Why an unprocessed thought can become physiological stress 00:19:30 – The sequence Darin follows before consuming anything stimulating 00:19:39 – Why cacao is part of Darin's morning ritual 00:20:06 – Darin reveals the cacao project he's developing 00:20:32 – The massive COSMOS cacao study 00:21:36 – Cacao and potential cognitive benefits 00:22:13 – Flavanols, nitric oxide, theobromine, magnesium, and polyphenols 00:22:50 – What to avoid when choosing cacao 00:23:19 – Darin's approach to resistance training 00:23:43 – Why movement doesn't need to be complicated 00:24:19 – Resistance training and longevity 00:24:54 – The powerful combination of strength training and aerobic activity 00:25:17 – Why walking may be one of the simplest longevity tools 00:25:46 – Muscle, blood sugar, myokines, and grip strength 00:26:15 – How injury changed Darin's relationship with training 00:26:51 – Training to experience more of life 00:27:14 – The principle the entire episode builds toward: food is information 00:27:26 – What you've learned from Darin's morning routine 00:27:49 – What Darin eats every day and his nighttime routine 00:28:18 – Continue Darin's complete daily protocol on Patreon Thank You to Our Sponsors: Bite Toothpaste: Go to trybite.com/DARIN20 or use code DARIN20 for 20% off your first order. Fatty15: Get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/DARIN and using code DARIN at checkout. Join the SuperLife Patreon: This is where Darin now shares the deeper work: - weekly voice notes - ingredient trackers - wellness challenges - extended conversations - community accountability - sovereignty practices Join now for only $7.49/month at https://patreon.com/darinolien Connect with Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness Key Takeaway "Your health isn't built from one perfect supplement, workout, meal, or morning routine. It's built from the information you repeatedly give your body. Light is information. Breath is information. Food is information. Movement is information. Darkness is information. Every day, your cells are listening to the signals you send them, whether you're consciously choosing those signals or allowing the modern world to choose them for you. You don't need to copy my routine. Understand why these practices matter, listen to your own body, and build a rhythm that works for your life. Because the seemingly insignificant things you do every morning, every afternoon, and every night eventually become your biology." Bibliography/Sources Morning Light Anderson, et al. (2025). Does sunlight exposure predict next-night sleep? A daily diary study among U.S. adults. Journal of Health Psychology . https://pubmed.ncbi.nlm.nih.gov/39077837/ Silva, et al. (2025). The role of sunlight in sleep regulation: Analysis of morning, evening and late exposure. BMC Public Health . https://link.springer.com/article/10.1186/s12889-025-24618-8 Meditation, Breath, Journaling Balban, et al. (2023). Brief structured respiration practices enhance mood and reduce physiological arousal. Cell Reports Medicine, 4(1), 100895 . https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(22)00474-8 Goyal, et al. (2014). Meditation programs for psychological stress and well-being: A systematic review and meta-analysis. JAMA Internal Medicine, 174(3), 357–368 . https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1809754 Pennebaker, J. W., & Beall, S. K. (1986). Confronting a traumatic event. Journal of Abnormal Psychology, 95(3), 274–281 . Smyth, et al. (2018). Online positive affect journaling… a preliminary randomized controlled trial. JMIR Mental Health, 5(4), e11290 . Cacao Sesso, et al. (2022). Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: COSMOS. The American Journal of Clinical Nutrition, 115(6), 1490–1500 . https://ajcn.nutrition.org/article/S0002-9165(22)00275-1/fulltext Vyas, et al. (2023). Cocoa extract and cognitive function: COSMOS clinic subcohort. The American Journal of Clinical Nutrition, 117(1), 40–52 . https://ajcn.nutrition.org/article/S0002-9165(23)66275-6/fulltext Resistance Training Saeidifard, et al. (2019). The association of resistance training with mortality. European Journal of Preventive Cardiology, 26(15), 1647–1665 . https://pubmed.ncbi.nlm.nih.gov/31104484/ Shailendra, et al. (2022). Resistance training and mortality risk: A systematic review and meta-analysis. American Journal of Preventive Medicine, 63(2), 277–285 . https://pubmed.ncbi.nlm.nih.gov/35599175/ Fruit, Nuts, Plant Diversity Aune, et al. (2016). Nut consumption and risk of CVD, cancer, all-cause mortality. BMC Medicine, 14, 207 . Aune, et al. (2017). Fruit and vegetable intake and the risk of CVD, cancer and all-cause mortality. International Journal of Epidemiology, 46(3), 1029–1056 . McDonald, et al. (2018). American Gut. mSystems, 3(3), e00031-18 . Tempeh Effects of fermented soy on cognition in older adults: RCT. (2025). . https://pmc.ncbi.nlm.nih.gov/articles/PMC12472887/ Stephanie, et al. (2018). Tempeh consumption enhanced beneficial bacteria in the human gut . https://www.researchgate.net/publication/328100975 Baru Nut Baru almond oil supplementation in hemodialysis patients: RCT. (2021). Clinical Nutrition . https://www.sciencedirect.com/science/article/abs/pii/S0965229920303575 de Souza, et al. (2019). Baru almonds increase the activity of glutathione peroxidase in overweight and obese women: RCT. Nutrients, 11(8), 1750 . https://www.mdpi.com/2072-6643/11/8/1750 Phenolic and flavonoid content, antioxidant capacity of baru almond. (2021). . https://pmc.ncbi.nlm.nih.gov/articles/PMC8181485/ Pumpkin Seeds Dotto, J., & Chacha, J. (2020). Pumpkin seeds as a functional food ingredient. Scientific African, 10, e00575 . U.S. Department of Agriculture. (n.d.). FoodData Central: Pumpkin seed kernels, dried . Avocado HAT: Life's Essential 8 ancillary. (2025). Journal of the American Heart Association . https://www.ahajournals.org/doi/10.1161/JAHA.124.039130 Lichtenstein, et al. (2022). HAT: 1 avocado/day vs habitual diet on visceral adiposity. Journal of the American Heart Association . https://pubmed.ncbi.nlm.nih.gov/35861827/ Unlu, et al. (2005). Carotenoid absorption enhanced by avocado. The Journal of Nutrition, 135(3), 431–436 . Evening Light, Sleep Environment Gooley, et al. (2011). Room light before bedtime suppresses melatonin onset. The Journal of Clinical Endocrinology & Metabolism, 96(3), E463–E472 . https://pubmed.ncbi.nlm.nih.gov/21193540/ Greco, et al. (2023). Eye mask during overnight sleep improves episodic learning and alertness. Sleep, 46(3) & Sleep, 46(8) . https://academic.oup.com/sleep/article/46/3/zsac305/6912219 https://academic.oup.com/sleep/article/46/8/zsad105/7143720 Hu, et al. (2010). Earplugs and eye masks on nocturnal sleep, melatonin and cortisol. Critical Care, 14(2), R66 . Mason, et al. (2022). Light exposure during sleep impairs cardiometabolic function. Proceedings of the National Academy of Sciences, 119(12) . https://www.pnas.org/doi/10.1073/pnas.2113290119 World Health Organization. (2018). Environmental noise guidelines for the European region . RF-EMF and Sleep Does radiofrequency radiation impact sleep? Double-blind, randomised, placebo-controlled crossover pilot. (2024). Frontiers in Public Health . https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2024.1481537/full Loughran, et al. (2005). Mobile phone EMF and human sleep. NeuroReport, 16(17), 1973–1976 . Mohler, et al. (2012). RF-EMF exposure and sleep quality: Prospective cohort. PLOS One, 7(5), e37455 .

Randomised controlled trials shape almost everything we do in the ICU. So why do so many of them seem to show nothing? And when a trial says "no benefit," what does that actually mean for the patient in front of you? This is the first episode of Beyond the P Value, a new eCritCare sub-series on interpreting RCTs in critical care with Professor Paul Young, intensivist and clinician researcher from New Zealand. Over the coming episodes, Dr Swapnil Pawar and Professor Young go past the abstract and the p-value to unpack how landmark ICU trials should be read, challenged and applied at the bedside. In this conversation: Why the RCT is still the gold standard for causal inference, and the three things to look at first: population, outcome, and plausibility of the treatment effect The two big weaknesses: surrogate outcomes that leave the patient out of the centre, and the gap between average effects and the individual patient Why "negative" trials never really fail, and how a neutral average can hide big benefit for some patients and big harm for others Individualised treatment effects, machine learning on trial datasets, and the coming oxygen target trial built on them Reinforcement learning in the ICU: how the Instagram feed model could one day balance treatments to maximise survival Availability bias at the bedside: why a rising blood pressure after a fluid bolus tells you almost nothing about outcome Heterogeneous populations, disease trajectories, and why you still have to start somewhere The collapsed right upper lobe that fixed itself, and what it says about how clinicians learn Where the practice-changing evidence actually lives: three journals, fewer than 20 papers a year, and the Critical Care Reviews meeting Next episode: how to interpret an RCT, and the anatomy of a trial. Read this episode on Substack: https://critcareedu.substack.com/p/beyond-the-p-value-why-rcts-matter

Send us Fan MailBen and Daphna dig into a pilot RCT that asks a deceptively simple delivery-room question: should very preterm infants start on CPAP of 5 or CPAP of 8 cmH2O? The PHILODENDRON trial, out of Milan's Buzzi Children's Hospital, randomized 56 babies born between 26 and 29 weeks to find out — testing feasibility, safety, and early physiological adaptation before committing to a larger multicenter trial. No major safety signals emerged, but babies on lower CPAP reached surfactant thresholds faster, while higher CPAP trended toward fewer air leaks and shorter ventilation. Ben and Daphna weigh the physiology against the data, and ask whether trials like this even test the right question in the first place.----Initial CPAP of 5 versus 8 cmH2O during delivery room stabilisation of very preterm infants: the PHILODENDROOM pilot randomised trial. Cavigioli F, Bresesti I, Castoldi F, Gatto S, Lupo E, Rossi S, La Verde A, Bianchi S, Meneghin F, Viaroli F, Pivetti V, Manfredini V, Cannata G, Bastrenta P, Fontana P, Stucchi I, Daniele I, Chiera M, Lista G.Eur J Pediatr. 2026 Aug 17;185(9):673. doi: 10.1007/s00431-026-07322-6.PMID: 42608615 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Mitch, Josh and special guest Dan Viens discuss the Seahawks vs Patriots Super Bowl rematch and Seahawks 13 - 10 win, in what was definitely a tale of 2 halves. We'll be discussing:

What research papers did you read while lounging by the pool this summer? In this week's episode of The Mindtools L&D Podcast, Ross D is joined by Claire and Dr Anna to review three studies that have caught our attention over the last few months. Anna's pick was Vestner and colleagues' 'A dyadic training to promote technology-related learning and development among age-diverse employees: the power of co-workers' enthusiasm', published in the Journal of Occupational and Organizational Psychology. Claire brought Kestin and colleagues' 'AI tutoring outperforms in-class active learning: an RCT introducing a novel research-based design in an authentic educational setting', the Harvard study comparing an AI tutor with in-person active learning. Ross referenced Will Thalheimer's LinkedIn article 'The Learning Styles Challenge After 20 Years', and Clinton-Lisell and Litzinger's 'Is It Really a Neuromyth? A Meta-Analysis of the Learning Styles Matching Hypothesis'. For more from Mindtools Kineo, visit our website mindtools-kineo.com. There, you'll find out how we can help your organization build AI skills, and how our Skills Practice scenarios help build human skills. Connect with our speakers If you'd like to share your thoughts on this episode, connect with us on LinkedIn: Ross Dickie Claire Gibson Anna Barnett

Listen to the pod and take this 30 second survey to help us improve https://york.qualtrics.com/jfe/form/SV_5gNKGPMVAHdQS6aHow smart is a phone ban, really? With the UK's under-16s social media ban confirmed for spring 2027 and mobile phones now expected to be banned from every English school day by default, this episode of Mind the Kids tackles one of the biggest parenting and policy debates of our time: what does the evidence actually say about smartphones, social media and children's mental health?Hosts Dr. Jane Gilmour (Honorary consultant clinical psychologist and child development programme director at UCL) and Professor Umar Toseeb (Professor of Psychology at the University of York) are joined by Professor Lisa Henderson from the University of York, author of two Child and Adolescent Mental Health Journal papers: "Digital Safeguarding Incidents in Schools With and Without Smartphone Policies" and "Innovations in Practice: A Pilot Randomised Trial on Smartphone and Social Media Abstinence."In this episode we unpack:– What the UK's social media ban for under-16s actually means for platforms like TikTok, Instagram, YouTube and Snapchat– Why comparing the UK ban to Australia's isn't a fair like-for-like comparison– New pilot RCT data on smartphone and social media abstinence, sleep quality and wellbeing in adolescents– What happens to digital safeguarding incident reporting when schools introduce phone policies– The "lost generation" risk — teens already embedded in social platforms navigating an abrupt policy shift– Why parental phone habits predict children's smartphone use– The "Goldilocks" amount of social media time, and why moderate use isn't the enemyIf you work in education, child psychology, safeguarding, or you're a parent trying to make sense of the smartphone ban headlines, this conversation goes well beyond the soundbites.Mind the Kids is brought to you by ACAMH (Association for Child and Adolescent Mental Health), translating the latest child and adolescent mental health research into evidence-based conversation.

The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: Latest #s: EHR estimates from 6 large US medical systems, estimated prevalence of autoimmune Dz (AID) to be 15 million (4.6% US population); 34% have 2+ AID. Women have 2x risk. Sex ratio of 1.7:1 F:M. https://buff.ly/fYgRfZ0 POETYK PsA-1: Deucravacitinib in Biologic-Naïve PsA POETYK PsA-1 trial tested the disease modifying efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in PsA patients and was shown to be superior vs to placebo for clinical responses, patient-reported outcomes, https://t.co/VjwpCVKPz0 MoonLake announced positive phase 3 data from its IZAR-1 RCT using its dual A/F IL-17 inhibitor sonelokimab, showing significant responses at week 16: 66% ACR20, 42% ACR50, 41% minimal disease activity (MDA), & 61% PASI90 at week 16. a 2nd IZAR-2 PsA RCT is in progress https://t.co/eX0cxekRKG British Dermatology Biologics registry (BADBIR) 18976 #PSO pts had incidence serious infxns (SIE) 28 SEI/1000 Pt-Yrs; higher if they had prior infxn (79/1000 PYs). SIE signif lower w/ RIZankizumab (HR 0.74-.80) vs BROAD, ETN, other standards Rxs. SIE deaths rare (1.81/1000 PYs) https://t.co/GTr3DLCVXs 39 studies compared Juvenile systemic sclerosis (jSSc) & adult SSc. 935 jSSc vs 15,451 aSSc pts; jSSc had more diffuse cutaneous dz (70% vs 41%), more overlap myositis (33% vs. 5%), arthritis (33% vs 18%), digital ulcers (51% vs 20%), less renal crisis (0% vs 6%) & lower mortality jSSc (7.7% vs. 20.4%) https://t.co/vflarmwSyv Italian SPRING cohort of #SSc pts found only 5.3% (of 1689 pts) without the typical scleroderma pattern on nailfold change by NVC. They had milder dz, with less vascular dz (pitting scars 33 vs 48%), telangiectasias (52 vs 74%), calcinosis 3.4 vs 12%) & higher DLCOs at 12, 24, https://t.co/AoNAhVYfII Review of CAR-T 29 trials in systemic sclerosis (SSc): 27/29 target CD19 (other CD20, BCMA), 20/29 autologous. Only 2 RCTs; 1 w/ RTX comparator. Most included CREST. Schetts largest series had 6 dcSSc w/ skin/lung improvements. Need fewer & larger multicenter RCTs https://t.co/Me28HbaFhR SLE & Dermatomyositis rashes maybe classically red or violaceous in Whites,but different in people of color, where erythema often appears brown/violaceous, Gottron papules can be mistaken for "dry skin." This delays dx, especially in anti-MDA5+ RP-ILD, where rash may be the https://t.co/Savx5IOTcG Yesterday the EMA approved upadacitinib (Rinvoq) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo - the 1st therapy approved for the most common form of vitiligo. Based on positive results from the Phase 3 Viti-Up trials https://t.co/MMv5LjZclQ 3 Rx are FDA approved for hidradenitis supprativa (secukinumab, adalimumab, bimekizumab). New JAK1i Povorcitinib in STOP-HS1 and STOP-HS2 ph 3 PCTs (608/619 pts). Povo showed HiSCR50 ~42% vs PBO 29% @wk12. AE: acne, pharyngitis https://t.co/n3FJUOjNuo

This week's pod has everything: 1. DDI information and dosing for daraxonrasib, now FDA approved and commercially available for pancreatic cancer 2. A new standard of care (?) in HER(+) gastric cancers, and more nuance on HER2 positivity. And lots of diarrhea. 3. The largest RCT in primary CNS lymphoma Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Dr. Hasan Alogaily is a global expert in longevity, and he's here to cut through the noise. Peptides, supplement stacks and expensive therapies dominate the conversation online, but he says none of it matters if the basics aren't in place first. In this conversation, Hasan explains why lifestyle is the real foundation of a longer life, how often you should actually be getting your bloods checked, and why skipping your annual health check is a bigger risk than most people realise. Timestamps:  00:00 Introduction 00:09 Longevity vs health span: what is the actual difference? 04:00 The longevity pyramid and why Dubai has it upside down 06:41 The patient on 37 supplements who was still smoking 07:29 Peptides, RCT evidence, and what the science actually supports 09:30 Blue zones: movement and food as a cultural norm 11:06 "Lifestyle doesn't sell. It's not sexy enough till you're 80." 11:28 Why the blue zones data may not be what we think it is 14:06 Mental well-being and why no supplement addresses it 15:25 What health span medicine actually challenges about standard practice 16:01 "In my medical school, I was never taught to write an exercise prescription." 18:00 Ozempic, BPC157, and what the peptide space actually looks like 19:17 1 in 3 people in this region have fatty liver 22:10 Why even 10 minutes in the gym changes your mortality risk 23:13 Why muscle mass is a bank account you draw from later 24:29 Zone 2 cardio and the Maffetone formula 25:51 Why walking uphill on a treadmill might be all you need 29:29 "If you have an Emirates ID card, I guarantee you've got vitamin D deficiency." 33:13 Spencer's Harley Street story: two surgeons, one MRI, opposite advice 35:10 Spencer reveals his own lifestyle and Dr Hasan says it's really good, then asks the one question that reframes everything. 38:19 Sleep in Dubai and what the Arabic language reveals about why it matters 39:27 Wearables: the only two metrics that actually tell you anything 44:40 Spencer's 4:30am wake-up and whether he is getting enough sleep 47:08 Spencer books his health check at the clinic 48:49 "Do not pass go unless you've done a health check once a year." 50:03 End   Follow Spencer Lodge on Social Media: https://www.instagram.com/madeindubaipodcast/?hl=en https://www.facebook.com/profile.php?id=61586194260076 https://www.instagram.com/spencer.lodge/?hl=en https://www.tiktok.com/@spencer.lodge https://www.linkedin.com/in/spencerlodge/ https://www.youtube.com/c/SpencerLodgeTV  https://www.facebook.com/spencerlodgeofficial/   Follow Dr. Hasan Alogaily on Social Media:  https://www.instagram.com/dubaifamilydoc/ https://kingscollegehospitaldubai.com/dr/hasan-alogaily/ https://www.linkedin.com/in/dr-hasan-alogaily-mbbs-mrcgp-dipcd-iblm-icflm-6318a2171/

In this episode, Brett and Martin discuss a cluster RCT from the Journal of Hospital Infection that took a very different approach. The researchers used social network analysis to identify the people operating room nurses naturally turned to for advice and support. Six of these informal influencers were then trained as peer champions—not as auditors or compliance police, but as positive role models who could encourage better practice through their existing relationships.  Over 12 months, hand hygiene compliance increased from 41.8% to 79.2% in the intervention group, compared with an increase from 42.6% to 59.3% with standard education. The study also reported improvements in knowledge and team climate. But there is plenty to debate. Can we really attribute the reported reduction in surgical site infections to the intervention? And could we use the same idea to influence other IPC behaviours—perhaps getting the right people to model cleaning shared equipment, PPE use or other everyday safety behaviours?   Link to the paper is here: Ye L, Jia X, Zhengyuan C, Dan Y, Jinjing Z, Nana W. Social network analysis-informed peer champions for hand hygiene in the operating room: a cluster randomised controlled trial. J Hosp Infect 2026;171:113–9. https://doi.org/10.1016/j.jhin.2026.03.003  The other paper we mention is here: Seto WH, Ching TY, Yuen KY, Chu YB, Seto WL. The enhancement of infection control in-service education by ward opinion leaders. Am J Infect Control 1991;19(2):86–91. https://doi.org/10.1016/0196-6553(91)90044-d. 

In this episode, Brett and Martin discuss a cluster RCT from the Journal of Hospital Infection that took a very different approach. The researchers used social network analysis to identify the people operating room nurses naturally turned to for advice and support. Six of these informal influencers were then trained as peer champions—not as auditors or compliance police, but as positive role models who could encourage better practice through their existing relationships.  Over 12 months, hand hygiene compliance increased from 41.8% to 79.2% in the intervention group, compared with an increase from 42.6% to 59.3% with standard education. The study also reported improvements in knowledge and team climate. But there is plenty to debate. Can we really attribute the reported reduction in surgical site infections to the intervention? And could we use the same idea to influence other IPC behaviours—perhaps getting the right people to model cleaning shared equipment, PPE use or other everyday safety behaviours?   Link to the paper is here: Ye L, Jia X, Zhengyuan C, Dan Y, Jinjing Z, Nana W. Social network analysis-informed peer champions for hand hygiene in the operating room: a cluster randomised controlled trial. J Hosp Infect 2026;171:113–9. https://doi.org/10.1016/j.jhin.2026.03.003  The other paper we mention is here: Seto WH, Ching TY, Yuen KY, Chu YB, Seto WL. The enhancement of infection control in-service education by ward opinion leaders. Am J Infect Control 1991;19(2):86–91. https://doi.org/10.1016/0196-6553(91)90044-d. 

Today, we are taking a deep dive into a medical truth thatsounds completely counterintuitive, almost upside down, based on everything you think you know about women's health. But here's the kicker: it's actually nothing new at all. For over two decades, ever since the landmark Women'sHealth Initiative (WHI) study made global headlines back in 2002, the blanket narrative surrounding menopausal hormone therapy has been clear and persistent: hormones equal breast cancer risk. But there is a massive asterisk in thatscience that got completely lost in the media noise. While combination therapy with conjugated equine estrogens paired with medroxyprogesterone acetate (CEE +MPA) did show an increased risk, the story for estrogen-only therapy (mainly CEE) in women wh had a hysterectomy is entirely different. In fact, an overwhelming mountain of growing data shows that estrogen-only therapy is protectiveagainst both breast cancer incidence and breast cancer mortality. In this episode, we're unpacking the latest high-level evidence that cements this crucial distinction. We'll examine the broad statistical landscape, including a comprehensive meta-analysis by Qing et al. (officially set for the December 2026 issue of Annals of Medicine, following its ahead-of-print release in March 2026). Their work breaks down how randomized controlled trial data consistentlypoint to estrogen-only therapy having a protective effect, in stark contrast to combination therapy. We'll also dive into a brand-new Clinical Perspective published in mid-August 2026 in Obstetrics & Gynecology (the Green Journal) by Drs. Andrew Kaunitz and Jason Wright. They call urgent attention to this phenomenon, highlighting RCT meta-analyses that demonstrate a 23% reduction in breast cancer incidence with estrogen alone (RR = 0.77), alongside striking cohort data showing a dramatic risk reduction even in high-risk populations, like carriers of the BRCA mutation.  Listenin for details.1.     Wu Q, Shen L, Hu S, Yang R, Wang Y, Xue D, SunY, Ma H, Dai Z. Relationship between menopausal hormone therapy and incidencerisk of breast cancer: systematic review and meta-analysis. Ann Med. 2026Dec;58(1):2640244. doi: 10.1080/07853890.2026.2640244. Epub 2026 Mar.2.     Kaunitz, Wright. Menopausal Estrogen Therapy andRisk of Breast Cancer. Obstet Gynecol. Aug 20263.     Chlebowski RT, Aragaki AK, Pan K, et al.Randomized Trials of Estrogen-Alone and Breast Cancer Incidence: AMeta-Analysis. Breast Cancer Research and Treatment. 2024. 4.     Writing Group for the Women's Health InitiativeInvestigators. (2002). Risks and benefits of estrogen plus progestin in healthypostmenopausal women: Principal results from the Women's Health Initiativerandomized controlled trial. JAMA, 288(3), 321–333.

TL;DR NOVAH (No Violence At Home) was incubated by Charity Entrepreneurship (now Ambitious Impact) in 2024 to test a promising idea: preventing intimate partner violence through edutainment, in our case a serialised radio drama. Over the past two years we have produced and aired two seasons in Rwanda. We are currently evaluating our second season through a randomized controlled trial with 2,400 couples in Rwanda in partnership with Innovations for Poverty Action (IPA). Preliminary results are expected in October 2026. The end-line analysis is run by IPA and our academic partners, not by NOVAH. Edutainment to prevent intimate partner violence is promising, but it is still young as a field. We do not want to spend donor money scaling it unless the evidence shows it works at least as well as the strongest existing approaches. The RCT is what will tell us that. Therefore, before seeing those results, we want to make our decision rule public: We will scale our programming only if the RCT finds a statistically significant relative reduction of at least 5% in physical or sexual intimate partner violence prevalence. How quickly we proceed will depend on the size and certainty of the effect. Our current [...] ---Outline:(00:14) TL;DR(02:04) Background on NOVAH's cause area and intervention(04:03) How we are evaluating our impact(05:54) Our pre-commitment(07:10) What happens under each result?(07:14) Effect below 5%, or not statistically significant: pause and explore(07:47) Effect of 5%-20%: continue as planned(08:15) Effect above 20%: accelerate(08:33) Why did you choose a 5% reduction?(09:37) Is everything driven by this RCT?(10:55) Why make this public?(11:29) How you can hold us to this(12:00) Should more non-profits do this?(12:37) Final words(13:09) Learn more and get in touch(13:41) Appendix(13:47) Why do you use IPV-year instead of DALYs in your cost-effectiveness? --- First published: August 11th, 2026 Source: https://forum.effectivealtruism.org/posts/Lz42uekYDBmBweq9f/what-would-make-us-scale-or-stop-novah-s-pre-commitment --- Narrated by TYPE III AUDIO.

Nasal strips have been a fixture in pharmacy aisles and on athletes' faces for decades, sold on the promise of easier breathing, but the peer-reviewed evidence often tells a different story than the packaging does. We put nasal strips and internal dilators through the RCT wringer and sort out what these devices can and can't actually do, from your bedroom to the finish line. In this episode we will:Break down what the highest-quality evidence — a 2026 meta-analysis of 17 studies and nearly 500 patients — actually found for AHI, oxygen saturation, and sleep architecture across all nasal dilator typesSit with the placebo-strip finding out of the University of São Paulo, and what it reveals about the gap between subjective "I slept better" and objective, PSG-measured outcomesCompare internal dilators like Mute against external strips, and call out where manufacturer-cited stats diverge from the independent literatureHead onto the field and track: two competing systematic reviews on whether strips help runners and athletes, and why "very low certainty" evidence still shapes what gets marketed to youTo find out more about this week's podcast sponsor BreatheUp, please use the following link: https://breatheup.com/Original intro music Vigilanteology by Abhinav Singh (copyright 2026) Original outro music Vigilanteology (reprise) by Abhinav Singh (copyright 2026)Produced by: Maeve WinterMusic by: Dr. Abhinav Singh (@sleep_vigilante), all rights reservedMoreTwitter: @drchriswinterIG: @drchriwinterThreads: @drchriswinterBluesky: @drchriswinterThe Sleep Solution and The Rested ChildThanks for listening and sleep well!

Hosts: Ed Jones (Owner – Nutrition World) & Clint Powell A variety of topics to living a healthy life Presented by: Nutrition World www.nutritionw.com Broadcasting from the Nooga Dentistry Studio www.noogadentistry.com Production of: Whitfield Media Group www.vitalhealthradio.com Title: Beyond Cholesterol: The Heart Health Markers That Matter [0:00:00] – Intro: Lettuce Contamination, Social Media & Local Business Impact Discussion of “fear of lettuce,” limited to 15 states (not Tennessee) How social media amplifies food scares Local “Build a Salad” restaurant going out of business and timing around lettuce scare [0:04:39] – Back-to-School Immune Support: Oral Probiotics & Iodine Nasal Spray Back-to-school season and rise in colds/sicknesses Oral probiotics for kids: oral microbiome, throat/sinus benefits Iodine nasal spray for parents and teachers: safety, use during school/gym, personal routines of Ed and Clint [0:08:04] – Supplement Industry & Big Pharma Buyouts Thorne bought by Procter & Gamble for $3.8B History of pharma mocking “granola/hippie” supplement culture, now buying brands Many acquired supplement brands failing under pharma ownership Difference between pharma customers and nutraceutical users (education, mindset) Nutrition World's preference for privately owned brands [0:14:00] – Life Lessons from Flying & Racing: Doing the Hard but Right Thing Ed's story: practicing engine-out landings, re-learning best glide speed Insight: sometimes you must “point the nose down” (do the counterintuitive hard thing) to survive Clint's race-car analogy: “you go where you look” – look down the track, not at the wall [0:18:01] – Food Label Claims: Olive Oil vs. Avocado Oil Products UC Davis testing of products “made with olive oil” – most passed authenticity tests Avocado-oil-labeled products often failing purity tests Takeaway: be more skeptical of “made with avocado oil” claims [0:18:31] – Prostate Cancer & “Treating the Terrain,” Not Just the Tumor Dr. Gio (prostate-focused naturopath): focus on the ground cancer grows in Historical context from Stephen Paget's work on tumor “soil and seed” Lifestyle “soil-building” recommendations: Resistance training, walking 150 minutes/week Waist circumference < half your height Sleep, stress reduction, nutraceuticals, nutrient-dense diet [0:21:58] – Multivitamins, Carotid Stenosis & Functional Benefits COSMOS study: Centrum multivitamin and patients with carotid narrowing Reported improvements in physical function (walking, climbing stairs) and symptoms (shortness of breath, fatigue) Ed's extrapolation: better-designed multis (True Grace, Life Extension, etc.) likely offer even more benefit [0:22:30] – Post-Infectious Cough: Honey + Instant Coffee vs. Prednisone Double-blind RCT comparing: Honey + instant coffee paste Prednisone Guaifenesin Honey + instant coffee dramatically outperformed prednisone in reducing persistent cough frequency Discussion of guaifenesin's role, safety, and its regulatory history in health food vs. pharmacy channels [0:30:12] – Prednisone, COVID & Anxiety: Personal Case Story Guest Dr. Curt Dearing shares: Followed COVID protocol including prednisone Developed severe, prolonged anxiety afterward (twice) Realization that prednisone triggered it Ed's summary of prednisone side effects: bone loss, cataracts, muscle wasting, weight gain; okay short term, risky long term [0:33:30] – Cardiovascular Disease, Statins, & New Drug Lifendra (PCSK9 Inhibitor Pill) CV disease framed as leading cause of death for most people Introduction of Lifendra (oral PCSK9 inhibitor, from Merck) as “breakthrough” LDL-lowering drug Comparison with Repatha (injectable PCSK9 inhibitor) Curt's key points: Lifendra lowers LDL but does not show reduction in cardiovascular death, heart attack, or stroke (per Merck's own wording so far) Repatha's trial data: minimal impact on non-fatal events; no reduction in CV deaths vs. placebo Very high cost (~$300+/month out of pocket; heavy insurance burden) Critique of LDL obsession in cardiology Need to ask: Why is the cardiovascular system inflamed and oxidized? Ed & Curt's “terrain” model: Bad inputs: ultra-processed food, toxins, poor sleep, chronic stress, lack of sun/movement Missing inputs: nutrient-dense foods, minerals, omega-3s, organ meats, sunlight, sleep, movement Example of amlodipine: lowers BP numbers but may increase arterial calcification (calcium channel blocker) For people unwilling to change lifestyle, drugs may offer marginal benefit—but not true health [0:41:05] – Curt's Book & Lab Markers That Matter More Than LDL-C Curt's book: “Beyond Cholesterol: The Ultimate Guide to Testing and Supplements for Heart Health” Emphasis on better markers: ApoB, LDL particle size/number, calcium score, etc. Book's Amazon performance briefly noted (new release bestseller in its category) [0:44:32] – Alternatives to Statins & PCSK9s: Bergamot & Lifestyle Curt's hierarchy: Lifestyle (diet, exercise, stress, sleep) Targeted supplements like bergamot (citrus extract): lowers harmful particles such as ApoB and supports “good” LDL function Only then consider pharmaceuticals, and very selectively Skepticism about recommending Lifendra at all; strong bias toward non-drug approaches [0:45:28] – Dr. Wolfson, Mold, and Cardiovascular Terrain Ed & Curt's respect for Dr. Jack Wolfson, “The Natural Heart Doctor” Mention of mold as a major, under-recognized driver of cardiovascular disease Reference to Dr. Wolfson's educational resources and upcoming podcast plans [0:48:04] – Key Takeaways on Lifendra & Heart Prevention Strategy Lifendra will not fix: seed oils, glyphosate exposure, mold, bad sleep, chronic stress Terrain-building priorities: Real food, omega-3s, sunlight Toxin reduction Mitochondrial support Foundational supplements Contrast: drugs = band-aids with side effects; nutraceuticals = “side benefits” when used correctly [0:52:28] – Wrap-Up Ed mentions Sprouts selling lab-grown meat and his strong opposition Update on Oura Ring: now tracking nighttime blood pressure and importance of BP dipping Listener story: young man post–heart surgery credits Nutrition World's education and support with changing his life Final thanks to Dr. Dearing and closing outro  The post Radio Show / Podcast – August 9, 2026 first appeared on Vital Health Radio.

Jared is joined by Tim Cook who is Senior Lecturer in Physiotherapy at the University of Chichester, Advanced Physiotherapy Practitioner in the NHS, and doctoral researcher to discuss their new paper with Prof. Jeremy Lewis in the Journal of Manual & Manipulative Therapy: "Rethinking strength testing in rotator cuff-related shoulder pain: a clinical tradition that lacks muscle." Tim explains what pushed him to question routine strength testing in busy clinical practice, despite guidelines recommending it, and the pair dig into whether weakness is a cause of shoulder pain, a consequence of it, or something else altogether. They look at what subacromial anaesthetic injection studies reveal about pain versus true force output, and Tim reframes the classic "weak and painful shoulder" as the "flexible but painful shoulder," drawing parallels to other oversimplified clinical narratives like posture and core stability. They also make the case for when strength testing can still earn its keep; patient engagement, expectation violation, building confidence, and sporting or return-to-performance populations such as ACL limb symmetry index, before turning to Goodhart's Law and the risk of chasing the test rather than the outcome, and why isolated isometric tests may not translate to real-world, endurance-based shoulder tasks. Tim closes out with an update on his PhD: a reliability RCT on strength and pain-free assessment currently in press, and an upcoming scoping review on the proposed mechanisms of exercise for RCRSP. Key resources Cook, T., Lewis, J., & Powell, J. (2026). Rethinking strength testing in rotator cuff-related shoulder pain: a clinical tradition that lacks muscle. Journal of Manual & Manipulative Therapy, 34(3), 193–198. https://doi.org/10.1080/10669817.2026.2663623 Register for the complete shoulder online course Melbourne workshop details Connect with Jared: Jared on Instagram: @‌shoulder_physio Jared on X: @‌jaredpowell12 Tim on Instagram: @Timcookphysio See our Disclaimer here: The Shoulder Physio - Disclaimer

HEALTH NEWS   Review finds blueberry and grape polyphenols may improve vascular health Plant compound shows promise for treating rheumatoid arthritis at its source, study finds Screen Time at Ages 1 and 6 Linked to Lasting Learning and Memory Effects Some caffeinated drinks are linked to poorer memory Study: Morning Exercise Linked to Lower Daily Calorie Intake Compared to Evening Workouts   Review finds blueberry and grape polyphenols may improve vascular health Universidad Católica de Murcia (Spain), July 27 2026 (News-Medical) A recent review published in the journal Nutrients examined the evidence on the effects of blueberries, grapes, and their bioactive compounds on cardiovascular risk markers. In the present study, a comprehensive systematic literature search was conducted to identify randomized controlled trials (RCTs), systematic reviews, and meta-analyses published from January 2015 through April 2026.  Two systematic reviews and meta-analyses reported that grape polyphenols at doses exceeding 500 mg/day for at least 12 weeks significantly reduced C-reactive protein levels, while the other reported improvements in vascular function or BP in 84% of the human studies it assessed, including a significant reduction in systolic BP. One found a modest reduction in BP and improvement in endothelial function with flavan-3-ol foods, such as tea, apples, cocoa, and grape-derived products. Moderate- and high-quality RCTs reported improvements in lipid peroxidation, lipid profiles, flow-mediated dilation, diastolic BP, and paraoxonase activity. Resveratrol and blueberry RCTs mainly reported endothelial and vascular benefits, such as improved nitric oxide production and flow-mediated dilation and reduced BP and inflammatory markers. One high-quality RCT involving older men with metabolic syndrome showed significant improvements in arterial stiffness and endothelial function after six months of daily blueberry consumption.     Plant compound shows promise for treating rheumatoid arthritis at its source, study finds Guangzhou University of Chinese Medicine, July 27 2026 (Natural News) A plant-derived compound called obakulactone (OL) reduced swelling, inflammation and joint damage in rats with rheumatoid arthritis, according to a study published in Engineering.   The compound, a tetracyclic triterpenoid from the bark of Phellodendri cortex, also rebalanced immune activity and corrected disrupted fatty acid metabolismd. P. cortex has been used in traditional medicine and contains OL along with other constituents, Researchers tested OL in rats with rheumatoid arthritis, administering low, medium and high doses for 21 days. Treatment significantly reduced joint swelling and helped restore the normal structure of cartilage and the synovium, the tissue lining the joints, according to the report.   Blood tests showed dose-dependent decreases in inflammatory molecules including IL-1, IL-6, IL-17 and TNF, as well as rheumatoid arthritis markers RF, CCP-Ab, CRP and MMP-3, officials said. The compound also reduced abnormally high levels of CD3+ T cells and CD68+ macrophages within the joints and shifted macrophages from a proinflammatory M1 state toward an anti-inflammatory M2 state.   Screen Time at Ages 1 and 6 Linked to Lasting Learning and Memory Effects National University of Singapore & Zhejiang University (China), July 28, 2026 (SciTech Daily) A study that tracked children from age 1 through age 8 found that greater screen viewing time, especially during infancy and near the start of school, was associated with lower academic performance at age 9 and weaker working memory at age 10.5. The results indicate that when children use screens may matter as much as how long they spend using them. The World Health Organization (WHO) and the American Academy of Pediatrics advise avoiding screens before 18 to 24 months and limiting viewing to less than one hour per day between ages 2 and 5. Many children exceed those recommendations, yet previous research on screens and cognitive development has produced inconsistent results. The analysis included 502 children followed from infancy into middle childhood. Higher screen viewing during particular stages was associated with poorer academic results and weaker working memory later on. The clearest and most consistent relationships appeared during infancy and near school entry, suggesting that these may be especially sensitive periods for cognitive development. Children with greater total screen exposure across childhood also generally performed less well in school. Together, the findings suggest that both the timing and overall amount of viewing may have implications for learning and memory.   Some caffeinated drinks are linked to poorer memory Applied Science Private University (Jordan), July 28 2026 (News-Medical) A recent study in the Journal of Education and Health Promotion examined the association between caffeine-containing products and memory performance, anxiety, and stress among university students in Jordan. 204 students were ultimately included in the study.  Mild psychological distress was the most common category, with 38.2% reporting such symptoms. About four in ten reported mild depression, and over a quarter experienced moderate anxiety. Only a small minority showed severe or extremely severe stress. Caramel or nut-filled chocolate was the most frequently consumed item, reported by 54.9% of students, followed by Arabic coffee (40.2%) and red tea (35.8%). Milk chocolate was also popular, typically consumed once or twice a day. Dark chocolate was less common, while American coffee and green tea were less popular, and decaffeinated coffee was rarely chosen. Overall DASS scores, representing depression, anxiety, and stress symptoms, showed positive correlations with the consumption of dark chocolate, American/instant coffee, decaffeinated coffee, and red tea, indicating these items were linked to higher psychological distress scores. Memory ability was negatively associated with higher intake of American coffee, Arabic coffee, and soft drinks.  The authors note that chocolate and green tea also contain bioactive compounds such as cocoa flavanols and L-theanine, which may have contributed to these associations alongside caffeine.   Study: Morning Exercise Linked to Lower Daily Calorie Intake Compared to Evening Workouts Copenhagen University Hospital (Denmark), July 27 2026 (Natural News)   A new study has found that morning exercise was associated with lower calorie consumption throughout the day compared to evening workouts, according to the research. Participants who exercised in the morning consumed about 400 fewer calories at the post-workout meal and roughly 547 fewer calories over the full 24-hour period, the study reported.   The study, which involved 35 healthy young adults. Each participant completed 30 minutes of treadmill running multiple times under varying conditions: morning fasted, evening fasted for 12 hours or 6 hours, and morning or evening fed, the study stated. The repeated-measures design enabled researchers to compare the same person's responses across different scenarios, officials said. After evening sessions, participants reported higher hunger, a stronger desire to eat, and lower fullness compared to morning sessions, the study found. Those who worked out in the evening consumed about 400 more calories at the post-workout meal and roughly 547 more calories over the full day, according to the research.   The appetite advantage was attributed to circadian rhythms, researchers said. The hunger hormone ghrelin naturally rises in the evening, while satiety hormones are more active in the morning,.

Heart disease kills one person every 40 seconds. That number hasn't changed in 30 years. Dr. John Osborne, a preventive cardiologist with two doctorates and 29 years in practice, has spent his career on a single question: why do we screen for cancers that kill a few percent of us and do nothing for the disease that kills 40%? In this episode, Jeremy and Jason sit down with Dr. Osborne to get the real story on cardiac CT with AI — the imaging technology that can detect, quantify, and track arterial plaque at sub-millimeter resolution, years before symptoms appear. If you track your bloodwork, wear a fitness device, or consider yourself health-forward — this is the conversation that fills the gap nobody warned you about.(Note: This episode was originally published March 16th, 2026)Guest Link:https://clearcardio.com/Key Moments:00:00 — Dr. Osborne's case for preventive cardiology: why heart disease is the most under-screened killer02:43 — How cardiac CT evolved from "iPhone 0.5" to the 2026-era AI-powered tool he uses today05:35 — Why he gave up stress tests and heart caths in 2005 and never looked back08:16 — What AI actually adds: seeing and quantifying plaque invisible to the human eye, down to 0.1 cubic millimeters10:13 — When insurance pays for cardiac CT — and when it doesn't (the preventive gray zone)14:50 — The “cardiac colonoscopy” concept: the case for screening before symptoms, not after18:11 — Coronary artery calcium score: the accessible $100 starting point, and what it can and can't tell you31:54 — Lifestyle essentials: the 50% of risk that's modifiable regardless of genetics35:00 — Family history decoded: why your sibling's heart history matters more than your parents'36:12 — Nicotine myth-busting: Dr. Osborne on the "health guru" nicotine fad and why he thinks it's dangerous38:05 — Supplements under scrutiny: natokinase, fish oil, red yeast rice — what the actual RCT data says

What if a patient who is years — even decades — out from their stroke could still make meaningful gains in their affected arm? In this episode, host Erin Gallardo, PT, DPT, NCS, talks with Mason Hearn, PT, DPT, NCS, about Vivistim, the FDA-approved paired vagus nerve stimulation system for chronic ischemic stroke, and why the "paired" piece — stimulation delivered in the same moment as intensive, task-specific therapy — is what makes it work. Mason breaks down the triple-blinded RCT behind the device, why patients an average of three years post-stroke saw two to three times greater improvement on the Fugl-Meyer, and how the real-world results coming out of clinics are landing even higher. This episode gets into what the protocol actually asks of patients (90-minute sessions, three times a week, 300–500 reps), how at-home "swiping" turns everyday tasks like getting dressed or cutting into a baked potato into neuroplasticity-building practice, who is and isn't a candidate, and how therapists can think about screening and advocacy without feeling like they're "referring someone for surgery." It's a hopeful, practical conversation about giving chronic stroke survivors real agency over the next stage of recovery and the clinicians who can open that door for them. Learn more at: Vivistim.com https://www.vivistimacademy.com/ Here is the safety profile: http://www.Vivistim.com/safety  

Open vs partial nephrectomy, and open vs robotic prostatectomy - two large randomised trials that did not change surgical practice! Just as important to examine these in GU Cast Journal Club as to examine pivotal trials that did change practice. Today we discuss the EORTC Today we discuss the EORTC 30904 RCT looking at kidney cancer surgery (Eur Urol 2011), and the Brisbane randomised trial of open vs robotic prostatectomy conducted (Lancet 2016). We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Mexico City, MEX), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. AN emotional one as Carlos is heading home to Mexico soon! Links to papers below:1. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma Eur Urol 2011 2. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study Lancet 2016Even better on our YouTube channelAbout GU Cast Journal Club:Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

Polycystic Ovarian Syndrome has been renamed Polyendocrine Metabolic Ovarian Syndrome. So seems like a good time to review our previous episode on it as we prep for a formal update on why the name change happened. Also, we hear Danielle's voice for the first time!!   Robyn Flynn joins Chris to talk about polycystic ovarian syndrome. More common than most people realize and with more far-reaching implications than it would initially seem. It can impact fertility, cardiovascular health, and according to Robyn is more painful than childbirth?!? We're going to have to look into that one.   You can also check out Robyn's podcast, Rebel Mom Boss https://open.spotify.com/show/4uMAsJS9ySR47iGYw8ExDo?si=bc68ddfcb0bd4f3f   Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE   Email us your questions at thebodyofevidence@gmail.com.   Editor:    Robyn Flynn Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer   Obviously, Chris not your doctor (probably). This podcast is not medical advice for you; it is what we call information.   References: 1) Dutch Twin study about the role of genetics in PCOS:   10.1210/jc.2005-1494   2) Cochrane review on meds that improve fertility https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003053.pub6/full   3) RCT of diet to restore fertility https://academic.oup.com/jcem/article-abstract/88/2/812/2845309?redirectedFrom=fulltext   4) Benefits of weight loss prior to fertility treatment 10.1210/jc.2016-1659 5) Letrozole vs. clomiphene for fertility treatment https://www.nejm.org/doi/full/10.1056/NEJMoa1313517 6) Metformin as a fertility treatment 10.1001/jamanetworkopen.2020.11995  

In this episode of the Prolonged Field Care Podcast, Dennis sits down with Dr. Andre Cap to unpack the evolving role of calcium in trauma resuscitation. What started as the “new hotness” in forward blood transfusion protocols has become far more nuanced. They discuss the dangers of both hypocalcemia and hypercalcemia, how citrate in all blood products binds ionized calcium, cardiac effects, recent observational data showing worse outcomes with hypercalcemia, and practical guidance for when, how, and how much calcium to give in austere and prolonged field care environments.Whether you're running a Role 2, working prolonged field care, or just trying to keep your patient alive until definitive care, this episode challenges long-held assumptions and offers field-practical recommendations.Key Takeaways:All blood products contain citrate, which binds ionized calcium — expect hypocalcemia with significant transfusion.Both hypo- and hypercalcemia are bad; recent data shows hypercalcemia is associated with worse mortality than hypocalcemia.Current TCCC guidance (1g calcium after first unit) was written to fix under-use; it may now be too aggressive in some scenarios.Give calcium after blood products, not before. Consider waiting until after 2+ units in most cases.Slow IV push (over ~5 minutes) through a confirmed good peripheral line; calcium chloride is a vesicant — use caution (gluconate is safer).Avoid calcium chloride via IO if possible. Titrate to clinical response when monitoring isn't available.In refractory shock you can give more, but don't give calcium as a standalone resuscitation drug — it can be harmful without volume replacement.Ideal future state: Bring i-STAT capability forward when feasible and get better RCT data.Perfect for medics, PAs, physicians, and anyone managing hemorrhagic shock in austere environments.Links:⁠www.prolongedfieldcare.org⁠ | @prolonged_field_carePodcast Chapters (with Timestamps):00:00 – Intro & Welcome00:39 – Why Calcium Became “The New Hotness” in Trauma Care01:18 – The Joint Trauma System Audit That Started It All03:46 – Citrate in Every Blood Product – The Science Behind the Bind05:44 – Why We Actually Care: Cardiac Repolarization, Contractility & Vascular Tone08:49 – Hypocalcemia vs Hypercalcemia in Trauma Patients10:21 – Shocking New Data: Hypercalcemia Carries Higher Mortality13:14 – TCCC Guidelines – After First Unit? Is This Too Aggressive?14:03 – When Should You Actually Give Calcium in the Field?19:34 – Clinical Triggers Without Monitoring + Dosing Strategy24:56 – Safety First: IV Patency, Calcium Chloride vs Gluconate, IO Concerns28:44 – When to Stop Giving Calcium & Avoiding Over-Correction32:00 – Historical Lessons: When Calcium Alone Made Things Worse33:39 – Practical PFC Recommendations & Final Thoughts38:04 – Closing & Where to Find MoreFor more content, go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.prolongedfieldcare.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Consider supporting us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/ProlongedFieldCareCollective⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.lobocoffeeco.com/product-page/prolonged-field-care⁠⁠⁠

Antenatal corticosteroids are a MAJOR win in the management of preterm labor. An initial course of antenatal corticosteroids has been shown to reduce morbidity and mortality in patients with preterm prelabor rupture of membranes. For patients who remain undelivered after the initial course of antenatal corticosteroids, it is uncertain whether a booster course of antenatal corticosteroids reduces neonatal morbidity or increases the infection risk. The ACOG, in its current guidance, has concluded that the current evidence is insufficient to make a recommendation. Corticosteroids, especially at the doses given, are also powerful immunosuppressants. When you administer that first course, you accept a minor, calculated risk for a massive, proven benefit. But when you introduce a second course of steroids into a uterine environment that has already been ruptured and exposed to vaginal flora for weeks, you are pouring fuel on the fire. PLUS, the environment for the fetus with prolonged preterm prelabor rupture of membranes is unique. PPPROM, the chronic exposure to ruptured membranes and the resultant oligohydramnios is theorized to trigger a kind of stress response in the fetus- so the baby may make their own endogenous corticosteroid flare. So, rescue steroids after an initial course of steroids in PPROM cases has remained controversial but we have updated data that has provided new insights. In this episode, we will highlight an RCT from 2023 and a more recent systematic review and meta-analysis from May 2026 on this very subject. Listen in for details. 1. Garite TJ, Kurtzman J, Maurel K, Clark R; Obstetrix Collaborative Research Network. Impact of a 'rescue course' of antenatal corticosteroids: a multicenter randomized placebo-controlled trial. Am J Obstet Gynecol. 2009 Mar;200(3):248.e1-9. doi: 10.1016/j.ajog.2009.01.021. Erratum in: Am J Obstet Gynecol. 2009 Oct;201(4):428. PMID: 19254583.2. Tenbrink E, Quain A, Rone V, Harris K, Hadley E, Haas D, Shanks A. Risk of Neonatal Sepsis With Rescue Steroids in Preterm Premature Rupture of Membranes. Cureus. 2023 Apr 6;15(4):e37207. doi: 10.7759/cureus.37207. PMID: 37159785; PMCID: PMC10163895.3. Melamed N, Murphy KE, Pylypjuk C, et al. Timingof Antenatal Corticosteroid Administration and Neonatal Outcomes. JAMA Netw Open. 2025;8(5):e2511315. 4. Porreco R, Garite TJ, Combs CA, Maurel K, Huls CK, Baker S, Fortner KB, Longo SA, Nageotte M, Lewis D, Tran L; Obstetrix Collaborative Research Network. Booster course of antenatal corticosteroids after preterm prelabor rupture of membranes: a double-blind randomized trial. Am J Obstet Gynecol MFM. 2023 May;5(5):100896. doi: 10.1016/j.ajogmf.2023.100896. Epub 2023 Feb 14. PMID: 36796641.5. Da Costa Y, Ramanathan V, Oliveira JA, Brito J, Yousif A. Repeat versus Single Course of Antenatal Corticosteroid in Management of Preterm Premature Rupture of Membranes: A Systematic Review and Meta-analysis. Am J Perinatol. 2026 May;43(7):925-932. doi: 10.1055/a-2708-5314. Epub 2025 Oct 9. PMID: 41067234

The Bakri Postpartum Balloon was described and first used clinically in 1999 by Dr. Younes N. Bakri (Georgia, USA). It is intended to treat postpartum hemorrhage (PPH). In the United States, it received its first major FDA clearance (via 510(k) for commercial marketing) on April 17, 2002. Manufacturer guidelines for the Bakri (Cook Medical) state that the balloon may be left indwelling for a maximum of 24 hours, but the determination of removal time is left to the clinician once “bleeding is controlled and the patient is stable.” However, the optimal duration of intrauterine balloon tamponade placement remains unclear. One retrospective cohort study from AJOG (Einerson et al) of 274 women found no significant difference in PPH outcomes when intrauterine balloon tamponade was left in place for 2–12 hours, compared with more than 12 hours. However, only 30 women had the intrauterine balloon tamponade placement for 10 hours or less. And remember, this was not a prospective trial looking at a minimum of 2 hours, 2 hours was just the lower margin of the “short duration” group. Now, a new RCT (with authors from Denver and Vermont) published in the July 2026 Green Journal provides new data. In this first of its kind pragmatic, randomized trial of noninferiority, a 6-hour duration of intrauterine balloon tamponade usage for postpartum hemorrhage (PPH) control was compared with an 18-hour duration. Listen in for details. 1. Durfee, J., Adkins, K., Heyborne, K., Larrea, N., & Schultz, C. (2026). Intrauterine Balloon Tamponade Duration for Postpartum Hemorrhage: A Randomized Controlled Trial. Obstetrics & Gynecology, 148(1), 113–120. https://doi.org/10.1097/AOG.00000000000062952. Garabedian C, Prats C, Seco A, Deneux-Tharaux C, Rozenberg P, Berveiller P. Duration of Intrauterine Balloon Tamponade in Post-Partum Haemorrhage Management After Vaginal Delivery: A Secondary Cohort Analysis From the French TUB Trial. BJOG. 2026 Jan;133(1):123-131. doi: 10.1111/1471-0528.18345. Epub 2025 Sep 1. PMID: 40888007; PMCID: PMC12676195.3. Einerson BD, Son M, Schneider P, Fields I, Miller ES. The association between intrauterine balloon tamponade duration and postpartum hemorrhage outcomes. Am J Obstet Gynecol 2017;216:300.e1–5.

Send us Fan MailIn this Journal Club, Ben and Daphna dig into two new papers on PDA management in our smallest patients. First, the SMART-PDA pilot RCT from Souvik Mitra and colleagues, which uses comprehensive hemodynamic screening to selectively treat high-volume shunts in infants born before 26 weeks, and whose striking Bayesian signal for reduced pulmonary hemorrhage and NEC stopped the trial early. Then a companion JAMA Network Open comparative effectiveness study across four pharmacotherapy regimens. Along the way, Ben shares hemodynamics pearls from his Montreal training: why left ventricular output, LA:Ao ratio, and transductal velocity matter more than PDA diameter alone.----Selective early medical treatment of the patent ductus arteriosus in extremely low gestational age infants: a pilot randomised controlled trial (SMART-PDA). Mitra S, Hebert A, Castaldo MP, Disher T, El-Naggar W, Dhillon S, Alhassen Z, Koo J, Katheria AC, Hyderi A, Kumaran K, Ting J, Surak A, Larocque J, Pepper D, Hornberger L, Makoni M, Weisz DE, Jain A, Bacchini F, Cameron-Nola AJJ, Hatfield T, Dorling J, McNamara PJ, Thabane L.Arch Dis Child Fetal Neonatal Ed. 2026 May 18:fetalneonatal-2026-330462. doi: 10.1136/archdischild-2026-330462. Online ahead of print.PMID: 42150872Pharmacologic Therapies for Patent Ductus Arteriosus in Extremely Preterm Infants. Mitra S, Jain A, Ting JY, Ben Fadel N, Drolet C, Abou Mehrem A, Soraisham AS, Jasani B, Louis D, Lapointe A, Dorling J, Khurshid F, Hyderi A, Kumaran K, Toye J, Harabor A, Weisz DE, Stavel M, Morin A, Bhattacharya S, Lalitha R, Afifi J, Augustine S, Castaldo MP, Hatfield T, Su YC, Shah PS; Canadian Neonatal Network Investigators.JAMA Netw Open. 2026 Jun 1;9(6):e2617477. doi: 10.1001/jamanetworkopen.2026.17477.PMID: 42262753 Free PMC article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

CardioNerds co-chairs Dr. Dinu Balanescu and Dr. Billy Joe Mullinax, along with FIT lead Dr. Shiavax Rao, discuss the evolving landscape of randomized controlled trials in pulmonary embolism with Dr. Jay Giri, interventional cardiologist, Associate Professor of Medicine, and Director of the Cardiovascular Catheterization Laboratories at the Hospital of the University of Pennsylvania. This episode examines the historical evidence behind systemic thrombolysis, the emergence of catheter-directed therapies and mechanical thrombectomy, and the landmark RCTs – STORM-PE, PEERLESS, HI-PEITHO, and PEERLESS II – that are reshaping intermediate-risk PE management. The discussion highlights challenges in PE trial design, the critical importance of clinical deterioration as an endpoint, and why this era represents an unprecedented wave of evidence generation in PE. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Dr. Dinu Balanescu and Dr. Billy-Joe Mullinax are Co-chairs for the CardioNerds PE Series, developed in collaboration with the PERT Consortium.   Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Pulmonary Embolism PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls: Systemic thrombolysis in intermediate-risk PE reduces hemodynamic decompensation but at the cost of ~1.5–2% intracranial hemorrhage risk – a near-zero net benefit that has driven the search for safer catheter-based alternatives. “Focus on clinical deterioration, not mortality” – Due to crossover design in contemporary PE RCTs, control-arm patients who decompensate are rescued with advanced therapies, biasing mortality toward the null. Clinical deterioration is the most informative endpoint to watch in HI-PEITHO, PRAGUE-26, and PEERLESS II. HI-PEITHO is the first large RCT to demonstrate that catheter-directed fibrinolysis plus anticoagulation significantly reduces the composite of PE-related death, cardiorespiratory decompensation, or PE recurrence versus anticoagulation alone (RR 0.39; 95% CI 0.20–0.77; P=0.005), with no intracranial hemorrhage in either arm. The four major upcoming/recently reported PE RCTs (HI-PEITHO, PRAGUE-26, PEERLESS II, PE-TRACT) enroll progressively different risk populations – from the most enriched (HI-PEITHO) to the most permissive (PE-TRACT, which includes intermediate-low risk patients) – enabling a nuanced understanding of which patients benefit most from intervention. PE device clearance follows a fundamentally different FDA pathway than structural heart devices (single-arm safety/efficacy studies vs. mandated RCTs), yet market forces and clinical need have ultimately driven industry and government to sponsor large-scale RCTs – a lesson in how evidence development can evolve organically alongside regulatory frameworks. Notes: Notes drafted by Dr. Shiavax Rao. Question #1: What is the current evidence behind advanced PE therapies? Systemic thrombolysis: Sixteen RCTs over 40 years (1972–2014) enrolling nearly 2,000 patients have studied systemic thrombolysis in intermediate-risk PE. The landmark PEITHO trial (n=1,006) showed that tenecteplase reduced the composite of death or hemodynamic collapse (2.6% vs. 5.6%; P=0.015), driven primarily by reduced hemodynamic decompensation (1.6% vs. 5.0%; P=0.002). However, this came at the cost of increased major bleeding (6.3% vs. 1.5%; P

New results from first-of-its-kind randomized controlled trial on a ketogenic diet for schizophrenia and bipolar disorder with psychosis offer important insights into metabolic psychiatry and mental health treatment.In this interview, Dr. Bret Scher sits down with Dr. Julie Milder to walk through the study results, recently published in Schizophrenia Bulletin. As the first RCT in psychosis-spectrum conditions to publish in the peer-reviewed literature, it's an important step toward understanding how metabolic interventions may play a role in serious mental illness.Key insights from the study:In the 1-month randomized portion of the trial, the ketogenic group showed significant improvements in metabolic health markers compared to diet-as-usualPsychiatric symptoms trended toward improvement, but were not statistically significant at 1 monthParticipants who opted into the ketogenic extension part of the study (4 total months of keto), saw improvements in depression, cognition, and positive and negative symptoms.In this video, Dr. Milder also breaks down important additional context about the limitations of the study, including the length of the randomized portion of the trial and the variance in dietary support between the two diet groups.This study adds to growing evidence linking metabolic health and psychiatric conditions and explores whether ketogenic therapy may play a role in addressing underlying mechanisms.

This is an episode from VoxDev's new podcast series, Ideas in Development. This series has a separate podcast feed, where you can find every episode of Oliver Hanney's conversations on evidence.YouTube: https://www.youtube.com/watch?v=EacHFVRt9p4 Apple Podcasts: https://podcasts.apple.com/us/podcast/has-development-economics-lost-its-way/id1866874059?i=1000775748550 Spotify: https://open.spotify.com/episode/2Lcy3FrbBuoE2nj3cnhOAm?si=76aedb574426479e Audioboom: https://audioboom.com/posts/8924691-has-development-economics-lost-its-way Substack: https://ideasindevelopment.substack.com/p/has-development-economics-lost-its What should development economists be working on – and how does their work actually reach the people making decisions?Rachel Glennerster, President of the Center for Global Development, whose career spans the research and policy sides of development, joins Oliver Hanney to discuss her proposal for a radical simplification of aid, why she feels the micro-macro debate is largely a false one, the messy but vital process of building consensus, and what impactful careers look like in economics.In this wide-ranging conversation, we cover the Smart Buys evidence panels in education and how cross-disciplinary consensus gets built, her three-box framework for evidence-based policymaking, why AI tools move too fast for RCT-based procurement, and what it would take to fix development economics' concentration problem.

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this episode, we have three new pieces of research and a special interview later on discussing the recommendations of the National Screening Committee on prostate cancer screening in the UK.First up for research: nasal sprays versus the common cold. The BJGP reports on longer-term findings through this simple intervention. Can it help this age-old problem?Second, new kid on the block, orforglipron - could it replace SGLT2 inhibitors for management of type 2 diabetes?Third, home-based hypnotherapy. Can it help children struggling with functional abdominal pain or IBS? We have a RCT to tell us. Finally, our interview with Dr Liz Bancroft, consultant nurse in oncogentics research, and Natalia Norori, interim Head of Data and Evidence at Prostate Cancer UK join us to discuss the new recommendations from the National Screening Programme with targeted screening of men with BRCA2, why they made this recommendation and how this affects us in general practice, plus what we need to know for our patients about the government-backed trial, TRANSFORM.ReferencesProstate Cancer UK Information on NSC decisionProstate Cancer UK Health Professional NSC FAQsNational Screening Committee report on prostate cancer screeningBJGP Nasal sprays for the common coldLancet Nasal Sprays original paperLancet Orforglipron vs dapagliflozin and T2DMBJGP Hypnotherapy in children for abdo painNational Screening Committee report on prostate cancer screeningwww.nbmedical.com/podcast

The episode explains how to use minoxidil for hair loss, emphasizing that it supports follicles and prolongs the anagen phase but does not block DHT (with topical dutasteride mentioned as a scalp-focused DHT option). It reviews evidence that 5% topical minoxidil is optimal (better than 2% and superior to 10%), works best on the crown/vertex, and should be applied to the scalp—not the hair—with expectations set for gradual results and possible early shedding. Twice-daily topical use is recommended unless combined with 0.01% tretinoin, which can make once-daily use similarly effective, though irritation can occur. Microneedling combined with minoxidil is strongly recommended based on a 2013 RCT, with guidance on depth (0.5–1.0 mm), frequency, and waiting 12–24 hours (or longer with tretinoin) before applying minoxidil. The episode also compares oral minoxidil dosing, notes a 2024 RCT showing similar outcomes to topical at 5 mg, and details systemic side effects, monitoring, and cautions including pet toxicity with topical use.   Full Hair Loss Podcast — Wnt vs DHT https://www.youtube.com/watch?v=bswq-Qhfebs   Minoxidil + Microneedling — 2013 Study https://pmc.ncbi.nlm.nih.gov/articles/PMC3746236/   5% vs 2% Topical Minoxidil https://pubmed.ncbi.nlm.nih.gov/12196747/   5% vs 10% Topical Minoxidil https://pubmed.ncbi.nlm.nih.gov/31403367/   Minoxidil + 0.01% Tretinoin Study https://pubmed.ncbi.nlm.nih.gov/17902730/   Oral vs Topical Minoxidil — 2024 Study https://pmc.ncbi.nlm.nih.gov/articles/PMC11007651/   Topical Dutasteride Study https://pmc.ncbi.nlm.nih.gov/articles/PMC12405733/   Topical Minoxidil Drug Information https://medlineplus.gov/druginfo/meds/a689003.html   Oral Minoxidil Drug Information https://medlineplus.gov/druginfo/meds/a682608.html   Tretinoin Drug Information https://medlineplus.gov/druginfo/meds/a682437.html   Dutasteride Drug Information https://medlineplus.gov/druginfo/meds/a603001.html   Minoxidil Toxicity in Dogs and Cats https://pubmed.ncbi.nlm.nih.gov/34370845/   Sildenafil / Viagra Drug Information https://medlineplus.gov/druginfo/meds/a699015.html   Tadalafil / Cialis Drug Information https://medlineplus.gov/druginfo/meds/a604008.html   Show Notes   00:00 Welcome to the Hart2Heart Podcast 00:45 Minoxidil Basics 01:43 DHT And What It Misses 03:07 How Minoxidil Works 03:55 Best Areas To Treat 04:30 Choosing The Right Strength 05:55 Once Or Twice Daily 08:28 Applying It Correctly 10:10 Microneedling Protocol 15:17 Formulations And Routine 18:14 Topical Side Effects 19:34 Shedding And Pet Safety 20:44 Oral Minoxidil Overview 22:53 Dosing And Risks 27:39 Combining Oral And Topical 28:36 Final Takeaways The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

New evidence from the first-ever RCT shows ketogenic therapy can rapidly improve metabolic health in schizophrenia-spectrum and bipolar I disorders, and shows early signals of psychiatric improvement.In this video, Dr. Bret Scher breaks down this newly published study led by Dr. Judith Ford at UCSF: the first randomized controlled trial with peer-reviewed results investigating ketogenic therapy in people with schizophrenia-spectrum disorders and bipolar-1 disorder with psychotic features.You'll learn:How the study was designed (a 1-month randomized phase plus an optional 3-4 month single-arm extension)What happened in the first 30 days (clear improvements in metabolic markers; psychiatric outcomes showed trends that did not reach statistical significance in the randomized portion)What improved over longer follow-up in the extension phase (encouraging changes in metabolic health, cognition, and psychiatric measures)Why this matters for patients and families today, and what future, longer controlled trials need to confirmPublished in Schizophrenia Bulletin and funded by the NIMH and Baszucki Group, this study adds to the growing literature on the potential benefit of ketogenic therapy for psychiatric disorders.These results indicate the need for larger, extended randomized controlled trials to test the safety and efficacy of ketogenic therapy in patients living with serious mental illness.

Whether it's joint pain, fatigue, brain fog, poor sleep, hot flushes or anxiety, it can feel frustrating when symptoms linger long after treatment ends. For many people, supplements seem like a logical place to look for menopause support, but with endless products, conflicting advice and cupboards full of half-used bottles, how do you know what's actually worth taking?In this episode, I am once again joined by leading oncologist, researcher and integrative medicine specialist Professor Robert Thomas to explore the role supplements may play in supporting health and wellbeing after cancer.Make sure to have pen and paper ready, as I think you'll need it!In this episode, we discuss:Why so many cancer survivors turn to supplementsHow to identify what symptoms you're actually trying to supportWhich supplements have anti-cancer properties?Which supplements help with joint pain?Supplements that may help with sleepThe role of vitamin D, probiotics and omega-3What should I NOT have too much of?The debate around multivitamins after cancerCommon supplement mistakes that waste moneyCreatine: what we know and what we still don't know for cancer survivorsOne of the most powerful messages from this conversation is that there is rarely one magic supplement. Instead, the best results often come from understanding your symptoms, focusing on overall health and making informed decisions based on evidence rather than marketing.Episode Highlights:00:00 Introduction05:06 Discussing supplements with oncologists08:34 Discussing supplement safety and benefits11:13 Improving gut health in menopause16:03 Concerns about multivitamins and antioxidants17:52 Discussing supplements and deficiencies20:57 Understanding Mineral Intake from Food25:44 Discussing creatine vs collagen benefitsResourcesKeep Healthy: keep-healthy.com and https://keep-healthy.com/polyphenols/Rob's bestselling book "How to Live"About Dr Robert ThomasDr Robert Thomas is a Consultant Oncologist, Professor of Nutritional and Sports Science, researcher, author and Head of Integrative Oncology at UCLH. His work focuses on helping people combine conventional cancer treatments with evidence-based lifestyle strategies to improve outcomes and quality of life.He also leads a research unit that has designed landmark scientific studies which provide the evidence that guide nutritionists, support groups, doctors and patients across the World.As well as mainstream oncology studies, the team focuses on randomised trials that evaluate the impact of exercise, diet, gut health and natural therapies on cancer, long covid and exercise performance, menopause and cancer.This included 5 RCT's addressing hormone related symptons after breast cancer including patient choice as a primary end point.His latest two double blind RCTs, discovered that boosting dietary phytochemicals (with Yourphyto) and gut health (with Yourgutplus) slowed prostate cancer progression, improved erectile function and urinary symptoms and improved three key biomarkers of longevity.Dani's links:Join my NEW blog ‘Still Becoming' on Substack: https://substack.com/@danibinnington?r=1osz6a&utm_campaign=profile&utm_medium=profile-pageBuy my book ‘Navigating Menopause After Cancer': https://amzn.eu/d/07dUoYBbJoin the 12th September Thames Bridges Trek: https://fundraiseformenopauseandcancer.raiselysite.com/thamesbridgestrekultrachallengeSet up your own fundraiser: https://fundraiseformenopauseandcancer.raiselysite.com/fundraisingideasMentioned in this episode:Fundraiser Walk: And walk: https://fundraiseformenopauseandcancer.raiselysite.com/thamesbridgestrekultrachallenge Substack: https://danibinnington.substack.com/

Send us Fan MailNeonatal sepsis physiology, steroids, vasopressors, and moms.gov. A full week on The Incubator Journal Club.Adrianne and Nim open with a retrospective study from Toronto challenging the assumption that hypoxemic respiratory failure in septic preterm infants is driven by elevated pulmonary vascular resistance. The data points instead to left ventricular dysfunction as a key contributor, raising questions about the reflex to reach for nitric oxide first.Nim then reviews a double-blind RCT from northern India evaluating early hydrocortisone versus placebo in neonatal fluid-refractory shock. The primary outcome did not reach statistical significance, but an 11 percent absolute reduction in mortality and a 70 percent open-label crossover rate tell a story of their own.Adrianne closes the journal club with a double-blind RCT comparing norepinephrine to dopamine for neonatal septic shock, finding no significant difference in shock reversal at 30 minutes, though significant methodological limitations make the findings hard to act on.Eli and Ben close the week on Neo News with a look at the newly launched moms.gov and what clinicians should know before their patients bring it up.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Ebook: https://drive.google.com/file/d/1AUsxg05dXkKFeAa64kC0u16XynnSx68o/view?usp=drive_link Episode Description: Every peptide conversation right now is about GLP-1 drugs, BPC-157, and TB-500. Nobody is talking about the one with 50 years of published research that your body is already making and losing as you age. GHK-Cu is a naturally occurring tripeptide that declines by 60% between the ages of 20 and 60. That decline tracks directly with the loss of skin elasticity, slower wound healing, thinning hair, reduced collagen production, and rising inflammation. In randomized controlled trials it has outperformed Rogaine for hair growth, shown a 55% reduction in visible wrinkles, and been documented to positively affect the expression of over 4,000 human genes. Dr. G calls it his favorite peptide, and his partner uses it on her face every day. In this episode, you will learn:  • How GHK-Cu works as a copper delivery vehicle at the cellular level, why it modulates gene expression across 31% of the human genome, and what that means for tissue repair, inflammation, and biological aging  • The head to head randomized controlled trial where GHK-Cu outperformed minoxidil for hair count, follicle size, and the active growth phase of the hair cycle  • Exactly what to look for when buying GHK-Cu cream, why the peptide is chemically fragile, what packaging and pH range to require, and the red flags that tell you to walk away from a product Timestamps: 0:00 - Intro 1:44 - What GHK-CU Actually Is and How It Was First Discovered in 1973 3:10 - Why a 60% Decline in GHK-CU Between Ages 20 and 60 Tracks Directly With Aging 4:40 - What Makes GHK-CU Different From Every Other Popular Peptide 6:00 - How It Stimulates Collagen, Elastin & the Extracellular Matrix 7:15 - The Human Trial Showing a 51% Increase in Collagen Density From Topical Application 8:00 - The 4,000 Genes GHK-CU Affects (And What the Broad Institute Found) 9:30 - Anti-Inflammatory Effects: Why This Matters for Biological Aging 10:30 - Wound Healing, Angiogenesis & Tissue Repair Across Skin, Bone, Gut and Liver 11:30 - The 2022 RCT: 55.7% Reduction in Visible Wrinkles After 12 Weeks 12:30 - Hair Growth: Outperforming Minoxidil in a Head-to-Head Randomized Trial 14:30 - Why the Lower Dose (50mg/ml) Outperformed the Higher Dose 15:30 - Safety Profile, Contraindications & the "Copper Uglies" Explained 17:00 - How to Buy GHK-CU: Concentration, Packaging, pH & What to Avoid Learn more about your ad choices. Visit megaphone.fm/adchoices

Can turmeric really help with joint pain, inflammation and gut health after cancer? And why are so many people being told to avoid it?In this fascinating conversation, I sit down with leading oncologist, researcher and integrative medicine expert Professor Robert Thomas to unpack the science behind turmeric, gut health and cancer recovery.Prof Thomas shares why he believes many patients are receiving outdated advice about turmeric, explains where concerns about tamoxifen interactions originated, and explores what the latest research actually tells us. Together, we discuss the role of gut health in long-term wellbeing, why exercise remains one of the most powerful tools available after cancer, and how lifestyle medicine can work alongside conventional cancer treatments.In this episode, we discuss:The surprising evidence behind turmeric and cancerWhy turmeric became controversial in breast cancer careThe difference between turmeric, curcumin and supplementsGut health, inflammation and the microbiomeManaging joint pain and menopausal symptoms after cancerExercise as a tool to improve cancer outcomesHow integrative oncology combines medical treatment with lifestyle strategiesCommon myths surrounding supplements and cancerResourcesKeep Healthy: keep-healthy.com and https://keep-healthy.com/polyphenols/Rob's bestselling book "How to Live"Episode Highlights:00:00 Introduction09:33 Discussing hormone therapy options12:30 Discussing health and patient advocacy15:00 Discussing menopause treatments20:06 Turmeric's rise in health circles22:24 Antioxidant and anti-inflammatory benefits24:21 Curcumin study and dosage discussion28:01 Addressing turmeric's cancer misconceptions32:28 Simplifying Supplement ChoicesAbout Prof Robert Thomas:Thomas is a Consultant Oncologist, Professor of Nutritional and Sports Science, author, researcher and Head of Integrative Oncology at UCLH. He has published extensively on lifestyle medicine, cancer prevention and survivorship, and is passionate about helping patients make informed decisions about their health using evidence-based approaches.He also leads a research unit that has designed landmark scientific studies which provide the evidence that guide nutritionists, support groups, doctors and patients across the World.As well as mainstream oncology studies, the team focuses on randomised trials that evaluate the impact of exercise, diet, gut health and natural therapies on cancer, long covid and exercise performance, menopause and cancer.This included 5 RCT's addressing hormone related symptons after breast cancer including patient choice as a primary end point.His latest two double blind RCTs, discovered that boosting dietary phytochemicals (with Yourphyto) and gut health (with Yourgutplus) slowed prostate cancer progression, improved erectile function and urinary symptoms and improved three key biomarkers of longevity.Connect with us:For more information and resources visit our website: www.menopauseandcancer.org Or follow us on Instagram @menopause_and_cancerJoin our Facebook group: www.facebook.com/groups/menopauseandcancerchathub Mentioned in this episode:Substack: https://danibinnington.substack.com/ Fundraiser Walk: https://fundraiseformenopauseandcancer.raiselysite.com/thamesbridgestrekultrachallenge

The FiltrateJoel Topf kidneyboy.bsky.socialSwapnil Hiremath @hswapnil.medsky.social Pedro Teixeira @nephcrit.bsky.socialSpecial GuestsEwout J. Hoorn, Professor of Medicine Erasmus MC, Netherlands. One of the primary authors.Harish Seethapathy, Assistant physician at Massachusetts General HospitalEditingVipin VergheseThe Kidney Connection written and performed by Timothy YauShow Notes A Randomized Trial of Targeted Hyponatremia Correction in Hospitalized Patients in NEJM Evidence, in PubMed, in NephJCSeethapathy: Severe Hyponatremia Correction, Mortality, and Central Pontine Myelinolysis in NEJM EvidenceMacMillan: Osmotic Demyelination Syndrome in Patients Hospitalized with Hyponatremia in NEJM EvidenceSALSA: Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of Hypertonic Saline for Patients With Symptomatic Hyponatremia: The SALSA Randomized Clinical Trial in JAMA Internal MedicineSALT 1 and 2: Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia in NEJM Hyponatremia registry: Current treatment practice and outcomes. Report of the hyponatremia registry in Kidney InternationalThe Richard Sterns' article on the lower mortality with more severe hyponatremia: Mortality and Serum Sodium: Do Patients Die from or with Hyponatremia? in CJASNThe European Hyponatremia Guidelines: Clinical practice guideline on diagnosis and treatment of hyponatraemia in The European Journal of EndocrinologyThe American Hyponatremia Guidelines: Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations in American Journal of MedicineTreating hyponatremia: damned if we do and damned if we don't by Tom Berl in Kidney InternationalProspective (clamp) versus reactive (rescue) DDAVP in hyponatremia: Safety and efficacy of proactive versus reactive administration of desmopressin in severe symptomatic hyponatremia: a randomized controlled trial in Nature Scientific Reports and as covered in PBFluidsHelbert Rondon's RCT of urea Urea for Chronic Hyponatremia on ClinicalTrials.govTubular SecretionsSwapnil: Catfishing on CatNet: A Novel by Naomi Kritzer (Amazon)Harish: Disney CruiseEdward: Flesh: A Novel (Booker Prize Winner) by David Szalay (Amazon)Pedro: Scrubs reboot (IMDB)Joel: KIDNEYcon

Nurse Doza breaks down five signs your gut microbiome may be off — a history of antibiotics, brain fog, autoimmune issues, relentless sugar cravings, and not pooping every day. He explains how gut bacteria help shape neurotransmitters, blood sugar, and natural GLP-1, why so many issues trace back to the gut, and the simple steps — fasting, fermented foods, fish oil, and the Good Poops Protocol — that can help rebuild it from the inside out. FEATURED PARTNER — Good Poops Protocol (MSW Nutrition) This episode centers on rebuilding the gut microbiome, and the Good Poops Protocol is the bundle Nurse Doza built for exactly that — Gut, Liver Boost, and Berberine Plus working together over 60 days to support the intestinal lining, healthy bile flow, and blood-sugar metabolism. Berberine and L-glutamine are both studied for supporting the body's own GLP-1 production, making the protocol a practical starting point for the digestive issues discussed in this episode.

Lion’s Mane Mushroom and Brain Health: What Four Clinical Trials Actually Found Many stroke survivors and people managing cognitive decline more broadly eventually ask the same question: Is there anything beyond physiotherapy and medication that can actively support brain healing? Not symptom management. Actual repair. Lion’s Mane mushroom (Hericium erinaceus) is one compound that has gathered genuine clinical attention. It is not a cure, the human trial evidence is still limited in scale, and it is not a replacement for the fundamentals of brain health. But the mechanism is unusual, the safety profile is consistently good, and for anyone serious about their brain, the research warrants an honest look. Why Lion’s Mane Is Neurologically Unusual Most supplements that claim to support brain health cannot cross the blood-brain barrier, the tightly regulated membrane that controls what enters the brain. Without crossing it, any direct effect on brain tissue is limited. Lion’s Mane contains two families of bioactive compounds found almost nowhere else in nature. Hericenones come from the fruiting body, the visible mushroom. Erinacines come from the mycelium, the root-like underground network. Both stimulate the production of Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF). These are proteins the brain uses to grow new neurons, maintain existing ones, and strengthen the connections between them. Crucially, erinacine A, one of the key mycelium compounds, has been confirmed in preclinical studies to cross the blood-brain barrier. That is not a trivial distinction. It is one of the reasons researchers have taken this mushroom seriously. “These are proteins your brain uses to grow new neurons, maintain existing ones, and build and strengthen the connections between them. They are, in a very real sense, your brain’s repair and maintenance crew.” — Bill Gasiamis What the Human Clinical Trials Found Four published human clinical trials have examined Lion’s Mane. Here is what each found: Mori et al. (2009): In a randomised, double-blind, placebo-controlled trial, 30 older adults with mild cognitive impairment (MCI) took Lion’s Mane supplement or placebo for 16 weeks. The Lion’s Mane group showed significantly better cognitive function scores at weeks 8, 12, and 16. When supplementation stopped, scores declined again within four weeks, suggesting the effect was tied to ongoing intake, not a placebo response. Saitsu et al. (2019): A multicenter RCT tested 12 weeks of oral Lion’s Mane in older adults. Participants in the treatment group showed significant improvement on the Mini-Mental State Examination (MMSE) compared to placebo. No adverse effects were observed. Nagano et al. (2010): A 4-week RCT using Lion’s Mane-enriched cookies found significant reductions in self-reported depression and anxiety in women compared to placebo, suggesting effects extend beyond cognition to mood and emotional regulation, possibly via the gut-brain axis. Docherty et al. (2023): A double-blind pilot study from Northumbria University tested 41 healthy young adults aged 18–45. After a single dose, participants performed significantly faster on the Stroop task, a measure of cognitive processing speed and flexibility. After 28 days, there was a trend toward reduced subjective stress. This was a small study, and results should be interpreted cautiously, but it suggests Lion’s Mane effects are not limited to populations already experiencing cognitive decline. The Stroke-Specific Preclinical Data For stroke survivors, the preclinical research adds another dimension. In a 2014 animal study, erinacine A reduced brain infarct volume by 22–44% in ischemic stroke models (depending on dose), and significantly lowered pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α markers of the neuroinflammatory cascade that follows stroke. A 2022 study found that erinacine A helps preserve glutamate clearance in the brain after ischemic injury. Excess glutamate is one of the key mechanisms of neuronal death after stroke, so anything that helps regulate it post-injury is clinically relevant. These are animal studies. They do not translate directly to human outcomes. But they provide a biological rationale that supports why clinical researchers are now investigating Lion’s Mane in neurological recovery contexts. What the Research Does Not Yet Tell Us The limitations matter, and any honest assessment must include them. All four human trials are relatively small, none exceeds 100 participants. We do not yet have large-scale, long-term RCTs in stroke survivor populations specifically. The optimal dose, duration, and form (fruiting body vs mycelium vs dual extract) have not been established in human trials. Direct confirmation that erinacines cross the blood-brain barrier in humans rather than in animal models does not yet exist. Bill says it directly in the video: “The human trial data is still relatively limited in scale. We need larger, longer trials.” Practical Questions to Raise with Your Doctor If you are considering Lion’s Mane supplementation, the following questions are worth raising with your neurologist or GP: Is it safe alongside my current medications? Theoretical interactions exist with anticoagulants (warfarin, aspirin, clopidogrel) and antidepressants, not confirmed in human trials, but worth disclosing. Anyone on blood thinners following a stroke should have this conversation before starting. What form should I look for? Products should specify standardised hericenone content (fruiting body extract) or erinacine A content (mycelium extract). Products listed only as “mycelial biomass on grain” typically contain very low levels of active compounds and high levels of starch from the growth substrate. If the label does not specify active compound content, treat that as a quality flag. Are there any trials I could join? ClinicalTrials.gov lists current recruiting studies for Hericium erinaceus and cognitive function worth checking if you are interested in contributing to the evidence base. More information: https://recoveryafterstroke.com/book | Support the podcast: https://patreon.com/recoveryafterstroke *This blog is for informational purposes only and does not constitute medical advice. Please consult your doctor before making any changes to your health or recovery plan. The post Can a Mushroom Help Your Brain Heal? The Science Says Maybe appeared first on Recovery After Stroke.

Prehospital blood is one of the hottest debates in trauma resuscitation — and the evidence just got a lot more interesting. In this episode, Drs. Patrick Georgoff and Ayman Ali sit down with Dr. Ed Barnard, UK defense professor of emergency medicine and author of the landmark SWIFT trial, and Dr. Juan De Chesney, trauma surgeon and pioneer in prehospital blood programs, to break down what we actually know about getting blood to patients before they hit the doors. The SWIFT trial — the largest prehospital whole blood RCT to date — found no superiority of whole blood over component therapy, but the story is far more nuanced than a negative headline suggests. From the logistics of carrying blood on a helicopter to the stark reality that only 1.8% of US ground EMS carries any blood products at all, this conversation exposes both the progress and the enormous gaps that remain. Hosts: Ayman Ali, MD: Ayman Ali is a Behind the Knife fellow and general surgery PGY-4 at Duke Hospital.  Patrick Georgoff, MD @georgoff: Patrick Georgoff is faculty in the Department of Surgery at the Duke University School of Medicine where he serves as an Associate Professor of Trauma, Acute, and Critical Care Surgery and Trauma Medical Director. He is a leading educator and creator for Behind the Knife, a premier digital education platform and podcast advancing surgical training through innovative, high-yield multimedia content. Juan Duchesne, MD: Juan Duchesne is a trauma surgeon and Professor of Surgery serving as the Trauma Medical Director and Division Chief at the University of Mississippi Medical Center. His pioneering contributions to the field—particularly in whole blood and balanced resuscitation practices—have been honored with numerous accolades.  Ed Barnard, PhD FRCEM FIMC RCSEd, @edbarn @DefProfEM: Ed Barnard is an emergency physician and UK Defence Professor of Emergency Medicine, RCEM/NIHR Associate Professor, and Affiliated Assistant Professor at the University of Cambridge. He has sub-specialty training in pre-hospital and academic emergency medicine and possesses extensive experience in trauma, anaesthesia, and critical care across both civilian and military settings. His contributions to the field have been honored with five national research awards and a PhD - undertaken with the US Army in San Antonio, TX. This episode was sponsored by Teleflex, a global provider of medical devices. Learn more at teleflex.com and at the Teleflex Trauma and Emergency Medicine LinkedIn page. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Galactagogues and medications to boost milk production. Everything from oats to fenugreek to lactation cookies and prescription medications like metoclopramide and domperidone. Also, cow's milk protein allergy, reflux and baby's spit-up, the safety of alcohol while breastfeeding, and how to handle other prescription medications. Natalie Borden, an international board certified lactation consultant, joins Chris to debunk breastfeeding myths. Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE   Email us your questions at thebodyofevidence@gmail.com.   Editor:    Robyn Flynn Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer   Obviously, Chris is not your doctor (probably). This podcast is not medical advice for you; it is what we call information. References: Internet survey on patient use of lactation aides: https://pubmed.ncbi.nlm.nih.gov/37236347/ Cochrane 2020 on galactogogues: https://pubmed.ncbi.nlm.nih.gov/32421208/ 2023 RCT on lactation cookies: https://pubmed.ncbi.nlm.nih.gov/36921902/ The LactMed database: https://www.ncbi.nlm.nih.gov/books/NBK501922/

This week, primary care doctors Mark Ebell, Kate Rowland, Henry Barry and Gary Ferenchick discuss four new studies: whether water is better than diet drinks in diabetes, a new RCT of Paxlovid for COVID in contemporary patients, to switch or not to switch antiplatelet agents after a stroke, and the latest AHA 2026 dietary advice for heart health.Drinks for diabetes: ttps://pubmed.ncbi.nlm.nih.gov/41369640/ Antiplatelet agents after stroke on aspirin: https://pubmed.ncbi.nlm.nih.gov/41347302/ New Paxlovid trial: https://pubmed.ncbi.nlm.nih.gov/42019019/ AHA 2026 dietary guidance: https://pubmed.ncbi.nlm.nih.gov/41914202/

Send us Fan MailOpioid withdrawal dosing, intranasal breast milk, human milk fortification in Japan, neonatal dysphagia, and vaccine policy. A full week on the Incubator Journal Club.Ben opens with the Optimized NOW trial in JAMA: symptom-based dosing reduced time to medical readiness for discharge by nearly two and a half days in NOWS infants managed with Eat Sleep Console, and allowed 65% of pharmacologically treated infants to avoid scheduled opioids entirely.Daphna reviews a small RCT out of Turkey showing improved cerebral oxygenation and favorable vital sign trends after intranasal breast milk administration in preterm infants, adding to the growing tolerability data for this intervention.Ben then covers the JASMINE trial, a Phase 3 RCT in Japan showing significantly better weight gain velocity with an exclusive human milk diet in very low birth weight infants.Daphna closes with a retrospective cohort study on FEES-confirmed dysphagia in preterm infants. Of those who met criteria for evaluation, every single one had laryngeal penetration and 57% were aspirating.Ben and Eli close the week on the quiet dismantling of vaccine infrastructure in the US and what it means for the populations in your NICU.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailDeep-dive into a 2026 cardiology review paper claiming seed oils reduce inflammation, exposing misrepresentations of cited clinical trials, and detailing how oxidized Ω-6 fats trigger inflammation.Companion article: Click HERETOPICS DISCUSSED:Seed Oil Profiles: Typical seed oils like sunflower are high in linoleic acid (omega-6 PUFA), while canola is higher in monounsaturated fats and resembles olive oil.Review Paper Critique: The 2026 JACC review falsely claims sunflower oil reduce inflammation like olive oil, citing an RCT that showed benefits only for canola and olive.RCT Analysis: In Iranian women with metabolic issues, switching to canola or olive oil lowered CRP by increasing MUFA and decreasing PUFA intake; sunflower oil produced no change.CRP Biology: CRP responds to oxidized lipids and cellular damage patterns, rising with exercise or infection and marking oxidized Ω-6 metabolites in modern diets.Oxidized Lipids: Ω-6 fats in LDL and cardiolipin oxidize easily, generating 4-HNE, MDA, and other signals that trigger immune clearance, similar to bacterial threats.Sterile Inflammation: High dietary linoleic acid causes chronic immune activation without pathogens, potentially contributing to metabolic and cardiovascular issues.PRACTICAL TAKEAWAYS:Prioritize monounsaturated fats from olive or avocado oil over high-linoleic seed oils like standard sunflower or soybean for lower oxidative stress potential.Check labels for high-oleic versions of sunflower oil, which shift the profile toward monounsaturated fats.Evaluate nutrition claims by examining original studies and fatty acid compositions rather than accepting review summaries at face value.Support the showHealth Products by M&M Partners:AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models.OmegaQuant: At-home blood testing to see fatty acid profiles, including omega-3 fatty acids. Use link to see options and support M&M.SiPhox Health: Comprehensive, cost-effective bloodwork from the comfort of home. Use code TRIKOMES for 20% off.KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime)SporesMD: Premium mushrooms products (gourmet mushrooms, nootropics, research). Use code 'nickjikomes' for 20% off.For all the ways you can support my efforts

Outside of pregnancy, guidelines emphasize diabetes self-management education and support to facilitate informed decision making, self-care behaviors, problem solving, and active collaboration with health care professionals. This includes, in those with good health literacy, the concept of patient-led self-titration of basal insulin results which has data that it improves glycemic management compared with clinician-led titration for type 2 diabetes among nonpregnant adults. But what about for GDM? Can patient's self manage their BASAL insulin? In this episode, we will review a new RCT published in April 2026 in the Green Journal on this very subject. As novel as this is, it is not the first to report on this as it was also published (retrospective study in the UK) in 2022. This is a novel approach to insulin in GDM but there are some questions that remain. Listen in for details.1. Boonpattharatthiti K, Wechkunanukul K, Mayang N, et al . Comparison of Insulin Titration Strategies for Glycemic Control in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.Diabetes Care. 2025. 2. Valent, Amy M. DO, MCR; Barbour, Linda A. MD, MSPH. Insulin Management for Gestational and Type 2 Diabetes in Pregnancy. Obstetrics & Gynecology 144(5):p 633-647, November 2024. | DOI: 10.1097/AOG.00000000000056403. Wang, Xiao-Yu MD; Gabbe, Steven MD; Landon, Mark B. MD; Venkatesh, Kartik K. MD, PhD et al. Patient-Led Insulin Titration for Glycemic Management With Gestational Diabetes Mellitus: A Randomized Controlled Trial. Obstetrics & Gynecology 147(4):p 501-509, April 2026. 4. McGovern AP, Hirwa KD, Wong AK, et al. Patient-led rapid titration of basal insulin in gestational diabetes is associated with improved glycaemic control and lower birthweight. Diabet Med. 2022;39:e14926. doi: 10.1111/dme.14926

Hyperemesis gravidarum (HG) represents the most severe end of the nausea and vomiting of pregnancy spectrum. It has a reported incidence of approximately 0.3–3% of pregnancies and is the most common cause of hospitalization in early pregnancy and the second most common cause of hospitalization in pregnancy overall. In June 2024, the ACOG published a Clinical Expert series summarizing the inpatient management of HG. In that guidance, it describes mirtazapine as an “alternative pharmacologic” option. How effective is this medication compared to ondansetron? A new study (published ahead of print on 12/30/25 and officially out June 2026), out of Denmark, sheds some new light on this medication. This trial is the first double-blind RCT comparing mirtazapine to ondansetron AND placebo. Although a BIG limitation of this study exists (which we will discuss), it does provide some interesting insights. Listen in for details.1. (ACOG CES) Clark, Shannon M. MD; Zhang, Xue MD; Goncharov, Daphne Arena MD. Inpatient Management of Hyperemesis Gravidarum. Obstetrics & Gynecology 143(6):p 745-758, June 2024. | DOI: 10.1097/AOG.00000000000055182. Ostenfeld, AnneDroogh, Marjoes et al.Mirtazapine or ondansetron for hyperemesis gravidarum. A randomized placebo-controlled trial. American Journal of Obstetrics & Gynecology, June 2026

Send us Fan MailCerebral oxygenation, staffing economics, delivery room scoring, neurodevelopmental prognostication, and public health — a full week on the Incubator Journal Club.Ben walks through the NIRTURE trial, a single-device RCT testing cerebral oximetry-guided care in infants born under 29 weeks. The intervention dramatically reduced the burden of cerebral hypoxia and hyperoxia compared to standard care. Secondary clinical outcomes were neutral and neurodevelopmental follow-up is still pending. The question of whether stabilizing cerebral oxygenation actually moves the needle for these babies remains unanswered.Daphna covers a brief communication from the Journal of Perinatology on what happens to billing and productivity when NICUs shift to 24-hour in-house attending coverage. Clinical FTE went up, work RVUs went down — and the reason is counterintuitive. Attendings present overnight were weaning babies faster. Better care, less revenue. The coding system was not built to capture that.Ben then pairs the 5-minute Apgar with umbilical artery pH in very preterm infants using EPICE cohort data. When both are low, risk is highest. When they compete, the Apgar wins.Daphna rounds out Journal Club with a systematic review showing that combining EEG and brain MRI outperforms either tool alone for neurodevelopmental prognostication in preterm infants.The week closes with Ben and Eli on the sweeping domestic and international public health funding cuts — and what they mean for the vulnerable populations in your NICU.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Listener feedback from the DanGer Shock investigators, complete vs staged revascularization, polygenic risk scores, and quality improvement failure in an RCT are the topics John Mandrola, MD, discusses in this week's podcast.   This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback DanGer Shock Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2312572 CHIP-BCIS 3 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2515704 II Immediate Complete vs Staged Revascularization in STEMI Meta-analysis: Timing of Complete Revasc in Patients with STEMI and Multivessel Disease https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.126.016601 COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775 FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149 iMODERN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2512918 III Polygenic Risk Scores for Prediction Polygenic Risk Report in US-Based Hospitals for 8 CV Conditions  https://www.jacc.org/doi/10.1016/j.jacc.2026.03.035 IV Practice Improvement Policies Undergo the Proper Test – Randomization Quality Improvement on Hospitalizations and Health Outcomes for People with CHD https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012904 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week's stories: *Bartonella Hides in Cat Scratches — and It Might Be Why You Feel Like Garbage A stealth bacterial infection transmitted by everyday cat scratches and flea dirt has been quietly linked to chronic fatigue, brain fog, and neurological symptoms for decades. Dave breaks down how Bartonella slips past standard testing, why it's almost never on a conventional doctor's radar, and the specific PCR protocol you need to actually find it. Sources: https://pubmed.ncbi.nlm.nih.gov/ *High Tyrosine Levels May Be Cutting Years Off Men's Lives A Mendelian randomization study of 270,000 UK Biobank participants found that elevated tyrosine is causally linked to nearly a full year of lost lifespan in men — with zero effect in women. The culprit appears to be an inflammatory oxidation pathway that men metabolize very differently. Dave examines what this means for every guy stacking L-tyrosine nootropics or eating high-protein keto. Sources: https://pubmed.ncbi.nlm.nih.gov/41045493/ https://www.aging-us.com/news-room/high-tyrosine-levels-linked-to-shorter-lifespan-in-men https://www.usnews.com/news/health-news/articles/2026-02-27/study-suggests-one-common-amino-acid-may-affect-how-long-men-live *Blue Light Blocking Contact Lenses Are a Legitimate Vision Upgrade ALTIUS Vision's tinted contact lenses aren't just blue light filters — they cut chromatic aberration by 53% and improve motion tracking and contrast sensitivity in ways that software filters simply can't replicate. Dave covers the mechanism, who benefits most (screen workers, TBI recovery, gamers), and how to find a provider. Sources: https://altiusvision.com/chromatic-aberration/ https://altiusvision.com/science-of-altius/ https://www.westvalleyvision.com/-altius--performance-tinted-contact-lenses *Taurine Plus B Vitamins Actually Moves the Needle on Motivation A randomized crossover trial found that a daily stack of taurine, B6, folate, and B12 sustained effort-reward motivation and cut cognitive lapses significantly compared to placebo — and the mechanism runs through glutathione production in brain astrocytes. Dave breaks down why this combo works when either ingredient alone doesn't. Sources: https://pubmed.ncbi.nlm.nih.gov/41889717/ https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2026.1711478/full https://www.nutraingredients.com/Article/2026/03/23/taurine-and-b-vitamins-bost-motivation-and-focus/ *30 Seconds of Smelling Flowers Resets Your Nervous System Research out of the Monell Chemical Senses Center confirms what your grandmother knew: a slow, deep floral inhale measurably lowers heart rate and activates the parasympathetic nervous system — and it works because olfaction bypasses the cortex entirely and hits the limbic system directly. Dave makes the case for building a daily scent ritual. Sources: https://time.com/ https://www.southtabor.com/healthy-living-tip-stop-and-smell-the-flowers/ This episode is designed for biohackers, longevity seekers, and high-performance listeners who want mechanism-level clarity on infection-driven cognitive decline, amino acid optimization, sensory performance, and evidence-based supplementation. Host Dave Asprey connects emerging clinical research, Mendelian randomization data, and real-world protocols into actionable frameworks for extending healthspan and sharpening performance. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: Bartonella cat scratch infection, Bartonella brain fog chronic fatigue, stealth bacterial infection biohacking, tyrosine lifespan men, L-tyrosine risk men longevity, Mendelian randomization amino acid aging, blue light blocking contacts, ALTIUS vision chromatic aberration, performance contact lenses TBI, taurine B vitamins motivation RCT, taurine folate brain health, glutathione astrocytes focus, smelling flowers heart rate stress, olfaction parasympathetic nervous system, floral scent limbic system, biohacking news, longevity research 2026 Thank you to our sponsors! - GOT MOLD? | Go to http://gotmold.com/shop and use DAVE10 to save 10% and see what's in your air. - MASA Chips | Go to https://www.masachips.com/DAVEASPREY and use code DAVEASPREY for 25% off your first order. - iRestore | Grow thicker, healthier hair back naturally. Use code DAVE at irestore.com. Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:37 – Bartonella & Cat Scratch Disease 02:06 – Tyrosine & Lifespan in Men 03:37 – Tinted Contacts & Visual Processing 05:56 – Taurine & Motivation 07:25 – Floral Scent & Nervous System Reset See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.